ACCESS DB # 265708
PLEASE PRINT CLEARLY

FOR OFFICIAL USE ONLY

RECEIVED
JUL -9 2008
CHEMICAL/BIOTECH (STIC)

RECEIVED
JUL
Scientific and Technical Information Center

SEARCH REQUEST FORM

(STIC)

Requester's Full Name: Savitha Rao Examiner # Date: 07/08/2008
Art Unit: 1614 Phone Number: 0-5315 Serial Number: 10590445
Location (Bldg/Room#): 2079 (Mailbox #): Results Format Preferred (circle): PAPER DISK

MG

To ensure an efficient and quality search, please attach a copy of the cover sheet, claims, and abstract or fill out the following:

Title of Invention: Methods & Materials for assessing prostate Cancer

Inventors (please provide full names): Michael E. Ingerval

Earliest Priority Date: 02/24/2004

Search Topic:
Please provide a detailed statement of the search topic, and describe as specifically as possible the subject matter to be searched. Include the elected species or structures, keywords, synonyms, acronyms, and registry numbers, and combine with the concept or utility of the invention. Define any terms that may have a special meaning. Give examples or relevant citations, authors, etc., if known.

**For Sequence Searches Only* Please include all pertinent information (parent, child, divisional, or issued patent numbers) along with the appropriate serial number.*

Please search the highlighted material in the attached claim set.

```
=> d ibib abs hitstr l8 1-2

L8   ANSWER 1 OF 2  HCAPLUS  COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER:          2006:1228845  HCAPLUS  Full-text
DOCUMENT NUMBER:           145:505452
TITLE:                     Preparation of diarylhydantoin compounds as androgen
                           receptor antagonists useful against hormone refractory
                           prostate cancer
INVENTOR(S):               Sawyers, Charles L.; Jung, Michael
                           E.; Chen, Charlie D.; Ouk,
                           Samedy; Welsbie, Derek; Tran, Chris;
                           Wongvipat, John; Yoo, Dongwon
PATENT ASSIGNEE(S):        The Regents of the University of California, USA
SOURCE:                    PCT Int. Appl., 166pp.
                           CODEN: PIXXD2
DOCUMENT TYPE:             Patent
LANGUAGE:                  English
FAMILY ACC. NUM. COUNT:    2
PATENT INFORMATION:

     PATENT NO.          KIND   DATE        APPLICATION NO.          DATE
     --------------      ----   --------    -------------------      --------
     WO 2006124118        A1    20061123    WO 2006-US11417          20060329
         W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
             CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
             GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR,
             KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX,
             MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE,
             SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC,
             VN, YU, ZA, ZM, ZW
         RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,
             IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ,
             CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH,
             GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
             KG, KZ, MD, RU, TJ, TM
     AU 2006248109        A1    20061123    AU 2006-248109           20060329
     CA 2608436           A1    20061123    CA 2006-2608436          20060329
     EP 1893196           A1    20080305    EP 2006-748863           20060329
         R:  AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,
             IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL,
             BA, HR, MK, YU
     US 20070004753       A1    20070104    US 2006-433829           20060515
     NO 2007006401        A     20080208    NO 2007-6401             20071212
     KR 2008014039        A     20080213    KR 2007-729188           20071213
     IN 2007DN09668       A     20080620    IN 2007-DN9668           20071213
PRIORITY APPLN. INFO.:                      US 2005-680835P     P    20050513
                                            US 2005-750351P     P    20051215
                                            US 2006-756552P     P    20060106
                                            US 2006-785978P     P    20060327
                                            WO 2006-US11417     W    20060329
OTHER SOURCE(S):           MARPAT 145:505452
GI
```



I



II

AB The present invention relates to diarylhydantoin compds., including diarylthiohydantoins (shown as I; variables defined below; e.g. N-methyl-4-[7-(4-cyano-3-trifluoromethylphenyl)-8-oxo-6-thioxo-5,7-diazaspiro[3.4]octan-5-yl]-2-fluorobenzamide (shown as II)), and methods for synthesizing them and using them in the treatment of hormone refractory prostate cancer. For I: X = trifluoromethyl and iodo; W = O and NR5; R5 = H, Me, and -C(:D)-E-G, (D is S or O and E is N or O and G is (un)substituted alkyl or aryl, or D is S or O and E-G together are C1-C4 lower alkyl); R1 and R2 together comprise eight or fewer C atoms and = (un)substituted alkyl including haloalkyl, and, together with the C to which they are linked, (un)substituted cycloalkyl; R3 = H, halogen, Me, C1-C4 alkoxy, formyl, haloacetoxy, trifluoromethyl, cyano, nitro, hydroxy, Ph, amino, methylcarbamoyl, methoxycarbonyl, acetamido, methanesulfonamino, methanesulfonyl, 4-methanesulfonyl-1-piperazinyl, piperazinyl, and C1-C6 alkyl or alkenyl (un)substituted with hydroxy, methoxycarbonyl, cyano, amino, amido, nitro, (un)substituted carbamoyl including methylcarbamoyl, dimethylcarbamoyl, and hydroxyethylcarbamoyl; R3 is not methylaminomethyl or dimethylaminomethyl; and R4 = H, halogen, alkyl, and haloalkyl. Methods of preparation are claimed and prepns. and/or characterization data for .apprx.60 examples of I are included. For example, II was prepared in 4 steps (91, 94, 89, 57 % yields, resp.) involving intermediates N-methyl-2-fluoro-4-nitrobenzamide, N-methyl-2-fluoro-4-aminobenzamide, and N-methyl-4-(1- cyanocyclobutylamino)-2-fluorobenzamide; the last step comprises cyclization of 4-isothiocyanato-2-trifluoromethylbenzonitrile (preparation given) with N-methyl-4-(1-cyanocyclobutylamino)-2-fluorobenzamide in DMF under microwave irradiation at 80° for 16 h followed by refluxing for 3 h after addition of MeOH and 2 N HCl.

IT 90357-06-5, Bicalutamide
RL: PAC (Pharmacological activity); BIOL (Biological study)
(comparison; preparation of diarylhydantoin compds. as androgen receptor antagonists useful against hormone refractory prostate cancer)

RN 90357-06-5 HCAPLUS

CN Propanamide, N-[4-cyano-3-(trifluoromethyl)phenyl]-3-[(4-fluorophenyl)sulfonyl]-2-hydroxy-2-methyl- (CA INDEX NAME)



IT 155180-53-3P, 4-[3-(4-Hydroxybutyl)-4,4-dimethyl-5-oxo-2-thioxoimidazolidin-1-yl]-2-trifluoromethylbenzonitrile
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(comparison; preparation of diarylhydantoin compds. as androgen receptor antagonists useful against hormone refractory prostate cancer)
RN 155180-53-3 HCAPLUS
CN Benzonitrile, 4-[3-(4-hydroxybutyl)-4,4-dimethyl-5-oxo-2-thioxo-1-imidazolidinyl]-2-(trifluoromethyl)- (CA INDEX NAME)



IT 915086-79-2P, 1-(4-Cyano-3-trifluoromethylphenyl)-3-[7-(4-cyano-3-trifluoromethylphenyl)-6-thioxo-5-(p-tolyl)-5,7-diazaspiro[3.4]octan-8-ylidene]thiourea
RL: PAC (Pharmacological activity); PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate, x-ray mol. structure; preparation of diarylhydantoin compds. as androgen receptor antagonists useful against hormone refractory prostate cancer)
RN 915086-79-2 HCAPLUS
CN Thiourea, N-[4-cyano-3-(trifluoromethyl)phenyl]-N'-[7-[4-cyano-3-(trifluoromethyl)phenyl]-5-(4-methylphenyl)-6-thioxo-5,7-diazaspiro[3.4]oct-8-ylidene]- (CA INDEX NAME)



IT 915086-29-2P, 4-[3-(4-Aminophenyl)-4,4-dimethyl-5-oxo-2-thioxoimidazolidin-1-yl]-2-trifluoromethylbenzonitrile 915086-32-7P, 4-[3-(4-Hydroxyphenyl)-4,4-dimethyl-5-oxo-2-thioxoimidazolidin-1-yl]-2-trifluoromethylbenzonitrile 915086-38-3P, 4-[8-Imino-6-thioxo-5-(4-methylphenyl)-5,7-diazaspiro[3.4]octan-7-yl]-2-trifluoromethylbenzonitrile 915086-81-6P, 4-[8-(4-Hydroxymethylphenyl)-5-oxo-7-thioxo-6-azaspiro[3.4]octan-6-yl]-2-trifluoromethylbenzonitrile 915086-82-7P, 4-[5-(4-Formylphenyl)-8-oxo-6-thioxo-5,7-diazaspiro[3.4]octan-7-yl]-2-trifluoromethylbenzonitrile 915086-84-9P 915086-87-2P, 3-[4-[7-(4-Cyano-3-trifluoromethylphenyl)-8-oxo-6-thioxo-5,7-diazaspiro[3.4]octan-5-yl]phenyl]propionic acid methyl ester 915086-88-3P, 3-[4-[7-(4-Cyano-3-trifluoromethylphenyl)-8-oxo-6-thioxo-5,7-diazaspiro[3.4]octan-5-yl]phenyl]propionic acid 915086-93-0P, 4-[4-[7-(4-Cyano-3-trifluoromethylphenyl)-8-oxo-6-thioxo-5,7-diazaspiro[3.4]octan-5-yl]phenyl]butyric acid methyl ester 915086-94-1P, 4-[4-[7-(4-Cyano-3-trifluoromethylphenyl)-8-oxo-6-thioxo-5,7-diazaspiro[3.4]octan-5-yl]phenyl]butyric acid 915086-95-2P, 4-[4-[7-(4-Cyano-3-trifluoromethylphenyl)-8-oxo-6-thioxo-5,7-diazaspiro[3.4]octan-5-yl]phenyl]butyramide 915086-96-3P, 4-[4-[7-(4-Cyano-3-trifluoromethylphenyl)-8-oxo-6-thioxo-5,7-diazaspiro[3.4]octan-5-yl]phenyl]-N-methylbutyramide 915087-00-2P, 4-[4-[7-(4-Cyano-3-trifluoromethylphenyl)-8-imino-6-thioxo-5,7-diazaspiro[3.4]octan-5-yl]phenyl]piperazine-1-carboxylic acid tert-butyl ester 915087-02-4P, 4-[8-Oxo-5-[4-(piperazin-1-yl)phenyl]-6-thioxo-5,7-diazaspiro[3.4]octan-7-yl]-2-trifluoromethylbenzonitrile 915087-09-1P, [4-[7-(4-Cyano-3-trifluoromethylphenyl)-8-oxo-6-thioxo-5,7-diazaspiro[3.4]octan-5-yl]phenyl]acetic acid methyl ester 915087-10-4P, [4-[7-(4-Cyano-3-trifluoromethylphenyl)-8-oxo-6-thioxo-5,7-diazaspiro[3.4]octan-5-yl]phenyl]acetic acid 915087-15-9P, 4-[3-(4-Cyano-3-trifluoromethylphenyl)-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl]benzoic acid methyl ester 915087-17-1P, Methanesulfonic acid [4-[7-(4-cyano-3-trifluoromethylphenyl)-8-oxo-6-thioxo-5,7-diazaspiro[3.4]octan-5-yl]phenyl]methyl ester 915087-21-7P, 4-[7-(4-Cyano-3-trifluoromethylphenyl)-8-oxo-6-thioxo-5,7-diazaspiro[3.4]octan-5-yl]benzoic acid methyl ester
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP

(Preparation); RACT (Reactant or reagent); USES (Uses)
(drug candidate; preparation of diarylhydantoin compds. as androgen receptor
antagonists useful against hormone refractory prostate cancer)

RN 915086-29-2 HCAPLUS
CN Benzonitrile, 4-[3-(4-aminophenyl)-4,4-dimethyl-5-oxo-2-thioxo-1-imidazolidinyl]-2-(trifluoromethyl)- (CA INDEX NAME)



RN 915086-32-7 HCAPLUS
CN Benzonitrile, 4-[3-(4-hydroxyphenyl)-4,4-dimethyl-5-oxo-2-thioxo-1-imidazolidinyl]-2-(trifluoromethyl)- (CA INDEX NAME)



RN 915086-38-3 HCAPLUS
CN Benzonitrile, 4-[8-imino-5-(4-methylphenyl)-6-thioxo-5,7-diazaspiro[3.4]oct-7-yl]-2-(trifluoromethyl)- (CA INDEX NAME)



RN 915086-81-6 HCAPLUS
CN Benzonitrile, 4-[8-[4-(hydroxymethyl)phenyl]-5-oxo-7-thioxo-6-azaspiro[3.4]oct-6-yl]-2-(trifluoromethyl)- (CA INDEX NAME)



RN 915086-82-7 HCAPLUS
CN Benzonitrile, 4-[5-(4-formylphenyl)-8-oxo-6-thioxo-5,7-diazaspiro[3.4]oct-7-yl]-2-(trifluoromethyl)- (CA INDEX NAME)



RN 915086-84-9 HCAPLUS
CN 2-Propenoic acid, 3-[4-[7-[4-cyano-3-(trifluoromethyl)phenyl]-8-oxo-6-thioxo-5,7-diazaspiro[3.4]oct-5-yl]phenyl]-, ethyl ester, (2E)- (CA INDEX NAME)

Double bond geometry as shown.



RN 915086-87-2 HCAPLUS
CN Benzenepropanoic acid, 4-[7-[4-cyano-3-(trifluoromethyl)phenyl]-8-oxo-6-thioxo-5,7-diazaspiro[3.4]oct-5-yl]-, methyl ester (CA INDEX NAME)



RN 915086-88-3 HCAPLUS
CN Benzenepropanoic acid, 4-[7-[4-cyano-3-(trifluoromethyl)phenyl]-8-oxo-6-thioxo-5,7-diazaspiro[3.4]oct-5-yl]- (CA INDEX NAME)



RN 915086-93-0 HCAPLUS
CN Benzenebutanoic acid, 4-[7-[4-cyano-3-(trifluoromethyl)phenyl]-8-oxo-6-thioxo-5,7-diazaspiro[3.4]oct-5-yl]-, methyl ester (CA INDEX NAME)



RN 915086-94-1 HCAPLUS
CN Benzenebutanoic acid, 4-[7-[4-cyano-3-(trifluoromethyl)phenyl]-8-oxo-6-thioxo-5,7-diazaspiro[3.4]oct-5-yl]- (CA INDEX NAME)



RN 915086-95-2 HCAPLUS
CN Benzenebutanamide, 4-[7-[4-cyano-3-(trifluoromethyl)phenyl]-8-oxo-6-thioxo-5,7-diazaspiro[3.4]oct-5-yl]- (CA INDEX NAME)



RN 915086-96-3 HCAPLUS
CN Benzenebutanamide, 4-[7-[4-cyano-3-(trifluoromethyl)phenyl]-8-oxo-6-thioxo-5,7-diazaspiro[3.4]oct-5-yl]-N-methyl- (CA INDEX NAME)



RN 915087-00-2 HCAPLUS
CN 1-Piperazinecarboxylic acid, 4-[4-[7-[4-cyano-3-(trifluoromethyl)phenyl]-8-imino-6-thioxo-5,7-diazaspiro[3.4]oct-5-yl]phenyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)



RN 915087-02-4 HCAPLUS
CN Benzonitrile, 4-[8-oxo-5-[4-(1-piperazinyl)phenyl]-6-thioxo-5,7-diazaspiro[3.4]oct-7-yl]-2-(trifluoromethyl)- (CA INDEX NAME)



RN 915087-09-1 HCAPLUS
CN Benzeneacetic acid, 4-[7-[4-cyano-3-(trifluoromethyl)phenyl]-8-oxo-6-thioxo-5,7-diazaspiro[3.4]oct-5-yl]-, methyl ester (CA INDEX NAME)



RN 915087-10-4 HCAPLUS
CN Benzeneacetic acid, 4-[7-[4-cyano-3-(trifluoromethyl)phenyl]-8-oxo-6-thioxo-5,7-diazaspiro[3.4]oct-5-yl]- (CA INDEX NAME)



RN 915087-15-9 HCAPLUS
CN Benzoic acid, 4-[3-[4-cyano-3-(trifluoromethyl)phenyl]-5,5-dimethyl-4-oxo-2-thioxo-1-imidazolidinyl]-, methyl ester (CA INDEX NAME)



RN 915087-17-1 HCAPLUS
CN Benzonitrile, 4-[5-[4-[[(methylsulfonyl)oxy]methyl]phenyl]-8-oxo-6-thioxo-5,7-diazaspiro[3.4]oct-7-yl]-2-(trifluoromethyl)- (CA INDEX NAME)



RN 915087-21-7 HCAPLUS
CN Benzoic acid, 4-[7-[4-cyano-3-(trifluoromethyl)phenyl]-8-oxo-6-thioxo-5,7-diazaspiro[3.4]oct-5-yl]-, methyl ester (CA INDEX NAME)



IT 915086-30-5P, 4-[3-(4-Azidophenyl)-4,4-dimethyl-5-oxo-2-thioxoimidazolidin-1-yl]-2-trifluoromethylbenzonitrile 915086-33-8P, Chloroacetic acid 4-[3-(4-cyano-3-trifluoromethylphenyl)-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl]phenyl ester 915086-35-0P, 4-[3-(4-Methylphenyl)-4,4-dimethyl-5-oxo-2-thioxoimidazolidin-1-yl]-2-trifluoromethylbenzonitrile 915086-36-1P, 4-(3-Phenyl-4,4-dimethyl-5-oxo-2-thioxoimidazolidin-1-yl)-2-trifluoromethylbenzonitrile 915086-39-4P, 4-[8-Oxo-6-thioxo-5-(4-methylphenyl)-5,7-diazaspiro[3.4]octan-7-yl]-2-trifluoromethylbenzonitrile 915086-40-7P, 4-[4-Oxo-2-thioxo-1-(4-methylphenyl)-1,3-diazaspiro[4.4]nonan-3-yl]-2-trifluoromethylbenzonitrile 915086-42-9P, 4-[4-Oxo-2-thioxo-1-(4-methylphenyl)-1,3-diazaspiro[4.5]decan-3-yl]-2-trifluoromethylbenzonitrile 915086-44-1P, 4-[4-Oxo-2-thioxo-1-(4-methylphenyl)-1,3-diazaspiro[4.6]undecan-3-yl]-2-trifluoromethylbenzonitrile 915086-47-4P, 4-[8-Oxo-6-thioxo-5-(4-hydroxyphenyl)-5,7-diazaspiro[3.4]octan-7-yl]-2-trifluoromethylbenzonitrile 915086-49-6P, 4-[8-Oxo-6-thioxo-5-(biphenyl-4-yl)-5,7-diazaspiro[3.4]octan-7-yl]-2-trifluoromethylbenzonitrile 915086-51-0P, 4-[8-Oxo-6-thioxo-5-(naphthalen-2-yl)-5,7-diazaspiro[3.4]octan-7-yl]-2-trifluoromethylbenzonitrile 915086-53-2P, 4-[4,4-Dimethyl-3-(4-methylpyridin-2-yl)-5-oxo-2-thioxoimidazolidin-1-yl]-2-trifluoromethylbenzonitrile

915086-55-4P, 4-[4,4-Dimethyl-3-(pyridin-2-yl)-5-oxo-2-thioxoimidazolidin-1-yl]-2-trifluoromethylbenzonitrile 915086-57-6P, 4-[5-(5-Methyl-1H-pyrazol-3-yl)-8-oxo-6-thioxo-5,7-diazaspiro[3.4]octan-7-yl]-2-trifluoromethylbenzonitrile 915086-58-7P, 4-[3-(4-Hydroxyphenyl)-4,4-dimethyl-2,5-dithioxoimidazolidin-1-yl]-2-trifluoromethylbenzonitrile 915086-59-8P, 4-[3-(4-Hydroxyphenyl)-4,4-dimethyl-2,5-dioxoimidazolidin-1-yl]-2-trifluoromethylbenzonitrile 915086-61-2P, 4-[4-Fluoromethyl-4-methyl-5-oxo-2-thioxo-3-(4-methylphenyl)imidazolidin-1-yl]-2-trifluoromethylbenzonitrile 915086-63-4P, 4-[4,4-Dimethyl-5-oxo-2-thioxo-3-(4-trifluoromethylphenyl)imidazolidin-1-yl]-2-trifluoromethylbenzonitrile 915086-65-6P, 4-[4,4-Bis(chloromethyl)-5-oxo-2-thioxo-3-(4-methylphenyl)imidazolidin-1-yl]-2-trifluoromethylbenzonitrile 915086-66-7P, 2-[3-(4-Cyano-3-trifluoromethylphenyl)-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl]benzoic acid 915086-68-9P, 4-[8-Oxo-6-thioxo-5-(2-methylphenyl)-5,7-diazaspiro[3.4]octan-7-yl]-2-trifluoromethylbenzonitrile 915086-71-4P, 4-[1-(4-Nitrophenyl)-4-oxo-2-thioxo-1,3-diazaspiro[4.4]nonan-3-yl]-2-trifluoromethylbenzonitrile 915086-72-5P, 4-[1-(4-Cyanophenyl)-4-oxo-2-thioxo-1,3-diazaspiro[4.4]nonan-3-yl]-2-trifluoromethylbenzonitrile 915086-75-8P, 4-[8-Methyl-4-oxo-2-thioxo-1-(4-methylphenyl)-1,3,8-triazaspiro[4.5]decan-3-yl]-2-trifluoromethylbenzonitrile 915086-76-9P, 4-[8-Methylimino-6-thioxo-5-(p-tolyl)-5,7-diazaspiro[3.4]octan-7-yl]-2-trifluoromethylbenzonitrile 915086-77-0P, 1-[3-(4-Cyano-3-trifluoromethylphenyl)-5,5-dimethyl-2-thioxo-1-(p-tolyl)imidazolidin-4-ylidene]-3-ethylthiourea 915086-78-1P, 1-[7-(4-Cyano-3-trifluoromethylphenyl)-6-thioxo-5-(p-tolyl)-5,7-diazaspiro[3.4]octan-8-ylidene]-3-phenylthiourea 915086-83-8P, 4-[5-[4-(1-Hydroxyethyl)phenyl]-8-oxo-6-thioxo-5,7-diazaspiro[3.4]octan-7-yl]-2-trifluoromethylbenzonitrile 915086-85-0P, 4-[5-[4-((E)-3-Hydroxyprop-1-enyl)phenyl]-8-oxo-6-thioxo-5,7-diazaspiro[3.4]octan-7-yl]-2-trifluoromethylbenzonitrile 915086-89-4P, 3-[4-[7-(4-Cyano-3-trifluoromethylphenyl)-8-oxo-6-thioxo-5,7-diazaspiro[3.4]octan-5-yl]phenyl]propionamide 915086-90-7P, 3-[4-[7-(4-Cyano-3-trifluoromethylphenyl)-8-oxo-6-thioxo-5,7-diazaspiro[3.4]octan-5-yl]phenyl]-N-methylpropionamide 915086-91-8P, 3-[4-[7-(4-Cyano-3-trifluoromethylphenyl)-8-oxo-6-thioxo-5,7-diazaspiro[3.4]octan-5-yl]phenyl]-N-(2-hydroxyethyl)propionamide 915086-97-4P, N-[4-[4-[7-(4-Cyano-3-trifluoromethylphenyl)-8-oxo-6-thioxo-5,7-diazaspiro[3.4]octan-5-yl]phenyl]butanoyl]methanesulfonamide 915086-98-5P, N-Methyl-4-[4-[7-(4-cyano-3-trifluoromethylphenyl)-6,8-dioxo-5,7-diazaspiro[3.4]octan-5-yl]phenyl]butyramide 915087-01-3P, 4-[4-[7-(4-Cyano-3-trifluoromethylphenyl)-8-[[(4-cyano-3-trifluoromethylphenyl)thiocarbamoyl]imino]-6-thioxo-5,7-diazaspiro[3.4]octan-5-yl]phenyl]piperazine-1-carboxylic acid tert-butyl ester 915087-03-5P, 4-[5-[4-(4-Methylsulfonylpiperazin-1-yl)phenyl]-8-oxo-6-thioxo-5,7-diazaspiro[3.4]octan-7-yl]-2-trifluoromethylbenzonitrile 915087-05-7P, (E)-3-[4-[7-(4-Cyano-3-trifluoromethylphenyl)-8-oxo-6-thioxo-5,7-diazaspiro[3.4]octan-5-yl]phenyl]acrylamide 915087-07-9P, 4-[5-(4-Methylsulfonylphenyl)-8-oxo-6-thioxo-5,7-diazaspiro[3.4]octan-7-yl]-2-trifluoromethylbenzonitrile 915087-11-5P, 2-[4-[7-(4-Cyano-3-trifluoromethylphenyl)-8-oxo-6-thioxo-5,7-diazaspiro[3.4]octan-5-yl]phenyl]acetamide 915087-12-6P, N-Methyl-2-[4-[7-(4-cyano-3-trifluoromethylphenyl)-8-oxo-6-thioxo-5,7-diazaspiro[3.4]octan-5-yl]phenyl]acetamide 915087-13-7P, N-[4-[3-(4-Cyano-3-trifluoromethylphenyl)-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl]phenyl]methanesulfonamide 915087-14-8P, N-[4-[3-(4-Cyano-3-

trifluoromethylphenyl)-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl]phenyl]acetamide 915087-16-0P, 4-[3-(4-Cyano-3-trifluoromethylphenyl)-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl]-N-methylbenzamide 915087-18-2P, 4-[5-[4-[(Methylamino)methyl]phenyl]-8-oxo-6-thioxo-5,7-diazaspiro[3.4]octan-7-yl]-2-trifluoromethylbenzonitrile 915087-19-3P, 4-[5-[4-[(Dimethylamino)methyl]phenyl]-8-oxo-6-thioxo-5,7-diazaspiro[3.4]octan-7-yl]-2-trifluoromethylbenzonitrile 915087-22-8P, N-(3-Cyano-4-trifluoromethylphenyl)-4-[7-(4-cyano-3-trifluoromethylphenyl)-8-oxo-6-thioxo-5,7-diazaspiro[3.4]octan-5-yl]benzamide 915087-23-9P, N-Methyl-4-[7-(4-cyano-3-trifluoromethylphenyl)-8-oxo-6-thioxo-5,7-diazaspiro[3.4]octan-5-yl]benzamide 915087-27-3P, N-Methyl-4-[7-(4-cyano-3-trifluoromethylphenyl)-8-oxo-6-thioxo-5,7-diazaspiro[3.4]octan-5-yl]-2-fluorobenzamide 915087-29-5P, 4-[5-(2-Fluoro-4-hydroxyphenyl)-8-oxo-6-thioxo-5,7-diazaspiro[3.4]octan-7-yl]-2-trifluoromethylbenzonitrile 915087-31-9P, 4-[1-(4-Cyano-3-fluorophenyl)-4-oxo-2-thioxo-1,3-diazaspiro[4.4]nonan-3-yl]-2-trifluoromethylbenzonitrile 915087-33-1P 915087-35-3P, 4-[3-[4-Cyano-3-(trifluoromethyl)phenyl]-4-oxo-2-thioxo-1,3-diazaspiro[4.4]nonan-1-yl]-2-fluoro-N-methylbenzamide 915087-40-0P, 4-[4-[7-[4-Cyano-3-(trifluoromethyl)phenyl]-8-oxo-6-thioxo-5,7-diazaspiro[3.4]octan-5-yl]phenyl]-N,N-dimethylbutanamide 915087-41-1P, 4-[5-[4-(3-Cyanopropyl)phenyl]-8-oxo-6-thioxo-5,7-diazaspiro[3.4]octan-7-yl]-2-(trifluoromethyl)benzonitrile 915087-42-2P 915087-43-3P 915087-44-4P 915087-45-5P 915087-46-6P 915087-47-7P 915087-48-8P 915087-49-9P 915087-50-2P 915087-51-3P 915087-52-4P 915087-59-1P 915087-60-4P 915087-62-6P 915087-63-7P 915087-64-8P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; preparation of diarylhydantoin compds. as androgen receptor antagonists useful against hormone refractory prostate cancer)

RN 915086-30-5 HCAPLUS

CN Benzonitrile, 4-[3-(4-azidophenyl)-4,4-dimethyl-5-oxo-2-thioxo-1-imidazolidinyl]-2-(trifluoromethyl)- (CA INDEX NAME)



RN 915086-33-8 HCAPLUS

CN Acetic acid, 2-chloro-, 4-[3-[4-cyano-3-(trifluoromethyl)phenyl]-5,5-dimethyl-4-oxo-2-thioxo-1-imidazolidinyl]phenyl ester (CA INDEX NAME)



RN 915086-35-0 HCAPLUS
CN Benzonitrile, 4-[4,4-dimethyl-3-(4-methylphenyl)-5-oxo-2-thioxo-1-imidazolidinyl]-2-(trifluoromethyl)- (CA INDEX NAME)



RN 915086-36-1 HCAPLUS
CN Benzonitrile, 4-(4,4-dimethyl-5-oxo-3-phenyl-2-thioxo-1-imidazolidinyl)-2-(trifluoromethyl)- (CA INDEX NAME)



RN 915086-39-4 HCAPLUS
CN Benzonitrile, 4-[5-(4-methylphenyl)-8-oxo-6-thioxo-5,7-diazaspiro[3.4]oct-7-yl]-2-(trifluoromethyl)- (CA INDEX NAME)



RN 915086-40-7 HCAPLUS
CN Benzonitrile, 4-[1-(4-methylphenyl)-4-oxo-2-thioxo-1,3-diazaspiro[4.4]non-3-yl]-2-(trifluoromethyl)- (CA INDEX NAME)



RN 915086-42-9 HCAPLUS
CN Benzonitrile, 4-[1-(4-methylphenyl)-4-oxo-2-thioxo-1,3-diazaspiro[4.5]dec-3-yl]-2-(trifluoromethyl)- (CA INDEX NAME)



RN 915086-44-1 HCAPLUS
CN Benzonitrile, 4-[1-(4-methylphenyl)-4-oxo-2-thioxo-1,3-diazaspiro[4.6]undec-3-yl]-2-(trifluoromethyl)- (CA INDEX NAME)



RN 915086-47-4 HCAPLUS
CN Benzonitrile, 4-[5-(4-hydroxyphenyl)-8-oxo-6-thioxo-5,7-diazaspiro[3.4]oct-7-yl]-2-(trifluoromethyl)- (CA INDEX NAME)



RN 915086-49-6 HCAPLUS
CN Benzonitrile, 4-(5-[1,1'-biphenyl]-4-yl-8-oxo-6-thioxo-5,7-diazaspiro[3.4]oct-7-yl)-2-(trifluoromethyl)- (CA INDEX NAME)



RN 915086-51-0 HCAPLUS
CN Benzonitrile, 4-[5-(2-naphthalenyl)-8-oxo-6-thioxo-5,7-diazaspiro[3.4]oct-7-yl]-2-(trifluoromethyl)- (CA INDEX NAME)



RN 915086-53-2 HCAPLUS
CN Benzonitrile, 4-[4,4-dimethyl-3-(4-methyl-2-pyridinyl)-5-oxo-2-thioxo-1-imidazolidinyl]-2-(trifluoromethyl)- (CA INDEX NAME)



RN 915086-55-4 HCAPLUS
CN Benzonitrile, 4-[4,4-dimethyl-5-oxo-3-(2-pyridinyl)-2-thioxo-1-imidazolidinyl]-2-(trifluoromethyl)- (CA INDEX NAME)



RN 915086-57-6 HCAPLUS
CN Benzonitrile, 4-[5-(5-methyl-1H-pyrazol-3-yl)-8-oxo-6-thioxo-5,7-diazaspiro[3.4]oct-7-yl]-2-(trifluoromethyl)- (CA INDEX NAME)



RN 915086-58-7 HCAPLUS
CN Benzonitrile, 4-[3-(4-hydroxyphenyl)-4,4-dimethyl-2,5-dithioxo-1-imidazolidinyl]-2-(trifluoromethyl)- (CA INDEX NAME)



RN 915086-59-8 HCAPLUS
CN Benzonitrile, 4-[3-(4-hydroxyphenyl)-4,4-dimethyl-2,5-dioxo-1-imidazolidinyl]-2-(trifluoromethyl)- (CA INDEX NAME)



RN 915086-61-2 HCAPLUS
CN Benzonitrile, 4-[4-(fluoromethyl)-4-methyl-3-(4-methylphenyl)-5-oxo-2-thioxo-1-imidazolidinyl]-2-(trifluoromethyl)- (CA INDEX NAME)



RN 915086-63-4 HCAPLUS
CN Benzonitrile, 4-[4,4-dimethyl-5-oxo-2-thioxo-3-[4-(trifluoromethyl)phenyl]-1-imidazolidinyl]-2-(trifluoromethyl)- (CA INDEX NAME)



RN 915086-65-6 HCAPLUS
CN Benzonitrile, 4-[4,4-bis(chloromethyl)-3-(4-methylphenyl)-5-oxo-2-thioxo-1-imidazolidinyl]-2-(trifluoromethyl)- (CA INDEX NAME)



RN 915086-66-7 HCAPLUS
CN Benzoic acid, 2-[3-[4-cyano-3-(trifluoromethyl)phenyl]-5,5-dimethyl-4-oxo-2-thioxo-1-imidazolidinyl]- (CA INDEX NAME)



RN 915086-68-9 HCAPLUS
CN Benzonitrile, 4-[5-(2-methylphenyl)-8-oxo-6-thioxo-5,7-diazaspiro[3.4]oct-7-yl]-2-(trifluoromethyl)- (CA INDEX NAME)



RN 915086-71-4 HCAPLUS
CN Benzonitrile, 4-[1-(4-nitrophenyl)-4-oxo-2-thioxo-1,3-diazaspiro[4.4]non-3-yl]-2-(trifluoromethyl)- (CA INDEX NAME)



RN 915086-72-5 HCAPLUS
CN Benzonitrile, 4-[1-(4-cyanophenyl)-4-oxo-2-thioxo-1,3-diazaspiro[4.4]non-3-yl]-2-(trifluoromethyl)- (CA INDEX NAME)



RN 915086-75-8 HCAPLUS
CN Benzonitrile, 4-[8-methyl-1-(4-methylphenyl)-4-oxo-2-thioxo-1,3,8-triazaspiro[4.5]dec-3-yl]-2-(trifluoromethyl)- (CA INDEX NAME)



RN 915086-76-9 HCAPLUS
CN Benzonitrile, 4-[8-(methylimino)-5-(4-methylphenyl)-6-thioxo-5,7-diazaspiro[3.4]oct-7-yl]-2-(trifluoromethyl)- (CA INDEX NAME)



RN 915086-77-0 HCAPLUS
CN Thiourea, N-[3-[4-cyano-3-(trifluoromethyl)phenyl]-5,5-dimethyl-1-(4-methylphenyl)-2-thioxo-4-imidazolidinylidene]-N'-ethyl- (CA INDEX NAME)



RN 915086-78-1 HCAPLUS
CN Thiourea, N-[7-[4-cyano-3-(trifluoromethyl)phenyl]-5-(4-methylphenyl)-6-thioxo-5,7-diazaspiro[3.4]oct-8-ylidene]-N'-phenyl- (CA INDEX NAME)



RN 915086-83-8 HCAPLUS
CN Benzonitrile, 4-[5-[4-(1-hydroxyethyl)phenyl]-8-oxo-6-thioxo-5,7-diazaspiro[3.4]oct-7-yl]-2-(trifluoromethyl)- (CA INDEX NAME)



RN 915086-85-0 HCAPLUS
CN Benzonitrile, 4-[5-[4-[(1E)-3-hydroxy-1-propen-1-yl]phenyl]-8-oxo-6-thioxo-5,7-diazaspiro[3.4]oct-7-yl]-2-(trifluoromethyl)- (CA INDEX NAME)

Double bond geometry as shown.



RN 915086-89-4 HCAPLUS
CN Benzenepropanamide, 4-[7-[4-cyano-3-(trifluoromethyl)phenyl]-8-oxo-6-thioxo-5,7-diazaspiro[3.4]oct-5-yl]- (CA INDEX NAME)



RN 915086-90-7 HCAPLUS
CN Benzenepropanamide, 4-[7-[4-cyano-3-(trifluoromethyl)phenyl]-8-oxo-6-thioxo-5,7-diazaspiro[3.4]oct-5-yl]-N-methyl- (CA INDEX NAME)



RN 915086-91-8 HCAPLUS
CN Benzenepropanamide, 4-[7-[4-cyano-3-(trifluoromethyl)phenyl]-8-oxo-6-

thioxo-5,7-diazaspiro[3.4]oct-5-yl]-N-(2-hydroxyethyl)- (CA INDEX NAME)



RN 915086-97-4 HCAPLUS
CN Benzenebutanamide, 4-[7-[4-cyano-3-(trifluoromethyl)phenyl]-8-oxo-6-thioxo-5,7-diazaspiro[3.4]oct-5-yl]-N-(methylsulfonyl)- (CA INDEX NAME)



RN 915086-98-5 HCAPLUS
CN Benzenebutanamide, 4-[7-[4-cyano-3-(trifluoromethyl)phenyl]-6,8-dioxo-5,7-diazaspiro[3.4]oct-5-yl]-N-methyl- (CA INDEX NAME)



RN 915087-01-3 HCAPLUS
CN 1-Piperazinecarboxylic acid, 4-[4-[7-[4-cyano-3-(trifluoromethyl)phenyl]-8-[[[[4-cyano-3-(trifluoromethyl)phenyl]amino]thioxomethyl]imino]-6-thioxo-

5,7-diazaspiro[3.4]oct-5-yl]phenyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)

PAGE 1-A



PAGE 2-A

RN 915087-03-5 HCAPLUS
CN Benzonitrile, 4-[5-[4-(methylsulfonyl)-1-piperazinyl]phenyl]-8-oxo-6-thioxo-5,7-diazaspiro[3.4]oct-7-yl]-2-(trifluoromethyl)- (CA INDEX NAME)



RN 915087-05-7 HCAPLUS
CN 2-Propenamide, 3-[4-[7-[4-cyano-3-(trifluoromethyl)phenyl]-8-oxo-6-thioxo-5,7-diazaspiro[3.4]oct-5-yl]phenyl]-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.



RN 915087-07-9 HCAPLUS
CN Benzonitrile, 4-[5-[4-(methylsulfonyl)phenyl]-8-oxo-6-thioxo-5,7-diazaspiro[3.4]oct-7-yl]-2-(trifluoromethyl)- (CA INDEX NAME)



RN 915087-11-5 HCAPLUS
CN Benzeneacetamide, 4-[7-[4-cyano-3-(trifluoromethyl)phenyl]-8-oxo-6-thioxo-5,7-diazaspiro[3.4]oct-5-yl]- (CA INDEX NAME)



RN 915087-12-6 HCAPLUS
CN Benzeneacetamide, 4-[7-[4-cyano-3-(trifluoromethyl)phenyl]-8-oxo-6-thioxo-5,7-diazaspiro[3.4]oct-5-yl]-N-methyl- (CA INDEX NAME)



RN 915087-13-7 HCAPLUS
CN Methanesulfonamide, N-[4-[3-[4-cyano-3-(trifluoromethyl)phenyl]-5,5-dimethyl-4-oxo-2-thioxo-1-imidazolidinyl]phenyl]- (CA INDEX NAME)



RN 915087-14-8 HCAPLUS
CN Acetamide, N-[4-[3-[4-cyano-3-(trifluoromethyl)phenyl]-5,5-dimethyl-4-oxo-2-thioxo-1-imidazolidinyl]phenyl]- (CA INDEX NAME)



RN 915087-16-0 HCAPLUS
CN Benzamide, 4-[3-[4-cyano-3-(trifluoromethyl)phenyl]-5,5-dimethyl-4-oxo-2-thioxo-1-imidazolidinyl]-N-methyl- (CA INDEX NAME)



RN 915087-18-2 HCAPLUS
CN Benzonitrile, 4-[5-[4-[(methylamino)methyl]phenyl]-8-oxo-6-thioxo-5,7-diazaspiro[3.4]oct-7-yl]-2-(trifluoromethyl)- (CA INDEX NAME)



RN 915087-19-3 HCAPLUS
CN Benzonitrile, 4-[5-[4-[(dimethylamino)methyl]phenyl]-8-oxo-6-thioxo-5,7-diazaspiro[3.4]oct-7-yl]-2-(trifluoromethyl)- (CA INDEX NAME)



RN 915087-22-8 HCAPLUS
CN Benzamide, N-[3-cyano-4-(trifluoromethyl)phenyl]-4-[7-[4-cyano-3-(trifluoromethyl)phenyl]-8-oxo-6-thioxo-5,7-diazaspiro[3.4]oct-5-yl]- (CA INDEX NAME)



RN 915087-23-9 HCAPLUS
CN Benzamide, 4-[7-[4-cyano-3-(trifluoromethyl)phenyl]-8-oxo-6-thioxo-5,7-diazaspiro[3.4]oct-5-yl]-N-methyl- (CA INDEX NAME)



RN 915087-27-3 HCAPLUS

CN Benzamide, 4-[7-[4-cyano-3-(trifluoromethyl)phenyl]-8-oxo-6-thioxo-5,7-diazaspiro[3.4]oct-5-yl]-2-fluoro-N-methyl- (CA INDEX NAME)



RN 915087-29-5 HCAPLUS
CN Benzonitrile, 4-[5-(2-fluoro-4-hydroxyphenyl)-8-oxo-6-thioxo-5,7-diazaspiro[3.4]oct-7-yl]-2-(trifluoromethyl)- (CA INDEX NAME)



RN 915087-31-9 HCAPLUS
CN Benzonitrile, 4-[1-(4-cyano-3-fluorophenyl)-4-oxo-2-thioxo-1,3-diazaspiro[4.4]non-3-yl]-2-(trifluoromethyl)- (CA INDEX NAME)



RN 915087-33-1 HCAPLUS
CN Benzamide, 4-[3-[4-cyano-3-(trifluoromethyl)phenyl]-5,5-dimethyl-4-oxo-2-thioxo-1-imidazolidinyl]-2-fluoro-N-methyl- (CA INDEX NAME)



RN 915087-35-3 HCAPLUS
CN Benzamide, 4-[3-[4-cyano-3-(trifluoromethyl)phenyl]-4-oxo-2-thioxo-1,3-diazaspiro[4.4]non-1-yl]-2-fluoro-N-methyl- (CA INDEX NAME)



RN 915087-40-0 HCAPLUS
CN Benzenebutanamide, 4-[7-[4-cyano-3-(trifluoromethyl)phenyl]-8-oxo-6-thioxo-5,7-diazaspiro[3.4]oct-5-yl]-N,N-dimethyl- (CA INDEX NAME)



RN 915087-41-1 HCAPLUS
CN Benzenebutanenitrile, 4-[7-[4-cyano-3-(trifluoromethyl)phenyl]-8-oxo-6-

thioxo-5,7-diazaspiro[3.4]oct-5-yl]- (CA INDEX NAME)



RN 915087-42-2 HCAPLUS
CN Thiourea, N-[4-cyano-3-(trifluoromethyl)phenyl]-N'-[3-[4-cyano-3-(trifluoromethyl)phenyl]-5-(fluoromethyl)-5-methyl-1-(4-methylphenyl)-2-thioxo-4-imidazolidinylidene]- (CA INDEX NAME)



RN 915087-43-3 HCAPLUS
CN Thiourea, N-[4-cyano-3-(trifluoromethyl)phenyl]-N'-[3-[4-cyano-3-(trifluoromethyl)phenyl]-5,5-dimethyl-1-(4-methylphenyl)-2-thioxo-4-imidazolidinylidene]- (CA INDEX NAME)



RN 915087-44-4 HCAPLUS
CN Thiourea, N-[4-cyano-3-(trifluoromethyl)phenyl]-N'-[3-[4-cyano-3-(trifluoromethyl)phenyl]-1-(4-hydroxyphenyl)-5,5-dimethyl-2-thioxo-4-imidazolidinylidene]- (CA INDEX NAME)



RN 915087-45-5 HCAPLUS
CN Carbamic acid, [3-[4-cyano-3-(trifluoromethyl)phenyl]-1-(4-hydroxyphenyl)-5,5-dimethyl-2-thioxo-4-imidazolidinylidene]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 915087-46-6 HCAPLUS
CN Benzonitrile, 4-[4,4-dimethyl-3-(4-methylphenyl)-5-oxo-2-thioxo-1-imidazolidinyl]-2-iodo- (CA INDEX NAME)



RN 915087-47-7 HCAPLUS
CN Benzonitrile, 4-[6-methyl-1-(4-methylphenyl)-4-oxo-2-thioxo-1,3-diazaspiro[4.4]non-3-yl]-2-(trifluoromethyl)- (CA INDEX NAME)



RN 915087-48-8 HCAPLUS
CN Benzonitrile, 4-[1-(4-methylphenyl)-4-oxo-2-thioxo-1,3-diazaspiro[4.7]dodec-3-yl]-2-(trifluoromethyl)- (CA INDEX NAME)



RN 915087-49-9 HCAPLUS
CN Benzonitrile, 4-[7-methyl-1-(4-methylphenyl)-4-oxo-2-thioxo-1,3-diazaspiro[4.4]non-3-yl]-2-(trifluoromethyl)- (CA INDEX NAME)



RN 915087-50-2 HCAPLUS
CN Thiourea, N-[4-cyano-3-(trifluoromethyl)phenyl]-N'-[7-[4-cyano-3-(trifluoromethyl)phenyl]-5-[4-(hydroxymethyl)phenyl]-6-thioxo-5,7-diazaspiro[3.4]oct-8-ylidene]- (CA INDEX NAME)



RN 915087-51-3 HCAPLUS
CN Benzonitrile, 4-[4-(fluoromethyl)-5-imino-4-methyl-3-(4-methylphenyl)-2-thioxo-1-imidazolidinyl]-2-(trifluoromethyl)- (CA INDEX NAME)



RN 915087-52-4 HCAPLUS
CN Benzonitrile, 4-[3-(4-iodophenyl)-4,4-dimethyl-5-oxo-2-thioxo-1-imidazolidinyl]-2-(trifluoromethyl)- (CA INDEX NAME)



RN 915087-59-1 HCAPLUS
CN Benzonitrile, 4-[3-(4-methoxyphenyl)-4,4-dimethyl-5-oxo-2-thioxo-1-imidazolidinyl]-2-(trifluoromethyl)- (CA INDEX NAME)



RN 915087-60-4 HCAPLUS
CN Benzonitrile, 4,4'-(4,4-dimethyl-5-oxo-2-thioxo-1,3-imidazolidinediyl)bis[2-(trifluoromethyl)- (CA INDEX NAME)



RN 915087-62-6 HCAPLUS
CN Benzonitrile, 4-[4,4-diethyl-3-(4-methylphenyl)-5-oxo-2-thioxo-1-imidazolidinyl]-2-(trifluoromethyl)- (CA INDEX NAME)



RN 915087-63-7 HCAPLUS
CN Benzonitrile, 4-[4-ethyl-4-methyl-3-(4-methylphenyl)-5-oxo-2-thioxo-1-imidazolidinyl]-2-(trifluoromethyl)- (CA INDEX NAME)



RN 915087-64-8 HCAPLUS
CN 2-Propenoic acid, 3-[4-[7-[4-cyano-3-(trifluoromethyl)phenyl]-8-oxo-6-thioxo-5,7-diazaspiro[3.4]oct-5-yl]phenyl]- (CA INDEX NAME)



IT 915087-53-5 915087-54-6 915087-55-7
915087-56-8 915087-57-9 915087-58-0
915087-61-5 915087-65-9 915087-66-0
RL: PAC (Pharmacological activity); BIOL (Biological study)
(preparation of diarylhydantoin compds. as androgen receptor antagonists useful against hormone refractory prostate cancer)

RN 915087-53-5 HCAPLUS
CN Benzonitrile, 4-[3-(4-methylphenyl)-5-oxo-2-thioxo-1-imidazolidinyl]-2-(trifluoromethyl)- (CA INDEX NAME)



RN 915087-54-6 HCAPLUS
CN Benzonitrile, 4-[4-methyl-3-(4-methylphenyl)-5-oxo-2-thioxo-1-imidazolidinyl]-2-(trifluoromethyl)- (CA INDEX NAME)



RN 915087-55-7 HCAPLUS
CN Benzonitrile, 4-[4-ethyl-3-(4-methylphenyl)-5-oxo-2-thioxo-1-imidazolidinyl]-2-(trifluoromethyl)- (CA INDEX NAME)



RN 915087-56-8 HCAPLUS
CN Benzonitrile, 4-[3-(4-methylphenyl)-5-oxo-4-propyl-2-thioxo-1-imidazolidinyl]-2-(trifluoromethyl)- (CA INDEX NAME)



RN 915087-57-9 HCAPLUS
CN Benzonitrile, 4-[3-(4-methoxyphenyl)-5-oxo-2-thioxo-1-imidazolidinyl]-2-(trifluoromethyl)- (CA INDEX NAME)



RN 915087-58-0 HCAPLUS
CN Benzonitrile, 4-[3-(4-methoxyphenyl)-4-methyl-5-oxo-2-thioxo-1-imidazolidinyl]-2-(trifluoromethyl)- (CA INDEX NAME)



RN 915087-61-5 HCAPLUS
CN Benzonitrile, 4,4'-(4-methyl-5-oxo-2-thioxo-1,3-imidazolidinediyl)bis[2-(trifluoromethyl)- (CA INDEX NAME)



RN 915087-65-9 HCAPLUS

CN Benzonitrile, 4,4'-(4-oxo-2-thioxo-1,3-imidazolidinediyl)bis[2-(trifluoromethyl)- (CA INDEX NAME)



RN 915087-66-0 HCAPLUS
CN Benzonitrile, 4-[3-(4-nitrophenyl)-5-oxo-2-thioxo-1-imidazolidinyl]-2-(trifluoromethyl)- (CA INDEX NAME)



IT 915086-70-3P, 4-(4-Oxo-2-thioxo-1,3-diazaspiro[4.4]nonan-3-yl)-2-trifluoromethylbenzonitrile
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent)
(preparation of diarylhydantoin compds. as androgen receptor antagonists useful against hormone refractory prostate cancer)
RN 915086-70-3 HCAPLUS
CN Benzonitrile, 4-(4-oxo-2-thioxo-1,3-diazaspiro[4.4]non-3-yl)-2-(trifluoromethyl)- (CA INDEX NAME)



IT 154262-93-8P, 4-(1-Methyl-4-oxo-2-thioxo-1,3-diazaspiro[4.4]nonan-3-yl)-2-trifluoromethylbenzonitrile 154262-97-2P, 4-(5-Methyl-8-oxo-6-thioxo-5,7-diazaspiro[3.4]octan-7-yl)-2-trifluoromethylbenzonitrile 154262-99-4P, 4-(1-Methyl-2,4-dioxo-1,3-diazaspiro[4.4]nonan-3-yl)-2-trifluoromethylbenzonitrile 154263-01-1P, 4-(5-Methyl-6,8-dioxo-5,7-diazaspiro[3.4]octan-7-yl)-2-trifluoromethylbenzonitrile 177338-09-9P, 4-(8-Methyl-4-oxo-2-thioxo-1,3,8-triazaspiro[4.5]decan-3-yl)-2-trifluoromethylbenzonitrile
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(preparation of diarylhydantoin compds. as androgen receptor antagonists useful against hormone refractory prostate cancer)

RN 154262-93-8 HCAPLUS
CN Benzonitrile, 4-(1-methyl-4-oxo-2-thioxo-1,3-diazaspiro[4.4]non-3-yl)-2-(trifluoromethyl)- (CA INDEX NAME)



RN 154262-97-2 HCAPLUS
CN Benzonitrile, 4-(5-methyl-8-oxo-6-thioxo-5,7-diazaspiro[3.4]oct-7-yl)-2-(trifluoromethyl)- (CA INDEX NAME)



RN 154262-99-4 HCAPLUS
CN Benzonitrile, 4-(1-methyl-2,4-dioxo-1,3-diazaspiro[4.4]non-3-yl)-2-(trifluoromethyl)- (CA INDEX NAME)



RN 154263-01-1 HCAPLUS
CN Benzonitrile, 4-(5-methyl-6,8-dioxo-5,7-diazaspiro[3.4]oct-7-yl)-2-

(trifluoromethyl)- (CA INDEX NAME)



RN 177338-09-9 HCAPLUS
CN Benzonitrile, 4-(8-methyl-4-oxo-2-thioxo-1,3,8-triazaspiro[4.5]dec-3-yl)-2-(trifluoromethyl)- (CA INDEX NAME)



IT 62-53-3, Aminobenzene, reactions 67-64-1, Acetone, reactions 75-86-5, Acetone cyanohydrin 91-59-8, 2-Aminonaphthalene 92-67-1, Biphenyl-4-amine 103-72-0, Phenyl thioisocyanate 106-49-0, p-Toluidine, reactions 106-50-3, 1,4-Diaminobenzene, reactions 108-94-1, Cyclohexanone, reactions 118-92-3, Anthranilic acid 120-92-3, Cyclopentanone 123-30-8, 4-Aminophenol 150-13-0, 4-Aminobenzoic acid 350-46-9, 4-Fluoronitrobenzene 394-41-2, 4-Nitro-3-fluorophenol 420-51-3, Fluoroacetone 455-14-1, 4-Trifluoromethylaniline 502-42-1, Cycloheptanone 504-29-0, 2-Aminopyridine 534-07-6, 1,3-Dichloroacetone 540-37-4, 4-Iodoaniline 542-85-8, Ethyl thioisocyanate 554-70-6, 4-Amino-2-trifluoromethylbenzonitrile 695-34-1, 2-Amino-4-methylpyridine 1191-95-3, Cyclobutanone 1194-02-1, 4-Fluorocyanobenzene 1197-55-3, 4-Aminophenylacetic acid 1427-07-2, 2-Fluoro-4-nitrotoluene 1445-73-4, 1-Methyl-4-piperidinone 2393-17-1, 3-(4-Aminophenyl)propionic acid 15118-60-2, 4-(4-Aminophenyl)butyric acid 24424-99-5, Di-tert-butyl pyrocarbonate 31230-17-8, 3-Amino-5-methylpyrazole 34667-86-4, 4-Nitro-2-fluorobenzonitrile 54356-04-6, (2-Carbethoxyethylidene)triphenylphosphorane 57260-71-6 177662-76-9, 4-Methylsulfonylphenylamine hydrochloride
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of diarylhydantoin compds. as androgen receptor antagonists useful against hormone refractory prostate cancer)

RN 62-53-3 HCAPLUS
CN Benzenamine (CA INDEX NAME)

RN 67-64-1 HCAPLUS
CN 2-Propanone (CA INDEX NAME)

RN 75-86-5 HCAPLUS
CN Propanenitrile, 2-hydroxy-2-methyl- (CA INDEX NAME)

RN 91-59-8 HCAPLUS
CN 2-Naphthalenamine (CA INDEX NAME)



RN 92-67-1 HCAPLUS
CN [1,1'-Biphenyl]-4-amine (CA INDEX NAME)



RN 103-72-0 HCAPLUS
CN Benzene, isothiocyanato- (CA INDEX NAME)

RN 106-49-0 HCAPLUS
CN Benzenamine, 4-methyl- (CA INDEX NAME)



RN 106-50-3 HCAPLUS
CN 1,4-Benzenediamine (CA INDEX NAME)



RN 108-94-1 HCAPLUS
CN Cyclohexanone (CA INDEX NAME)

RN 118-92-3 HCAPLUS
CN Benzoic acid, 2-amino- (CA INDEX NAME)

RN 120-92-3 HCAPLUS
CN Cyclopentanone (CA INDEX NAME)

RN 123-30-8 HCAPLUS
CN Phenol, 4-amino- (CA INDEX NAME)



RN 150-13-0 HCAPLUS
CN Benzoic acid, 4-amino- (CA INDEX NAME)



RN 350-46-9 HCAPLUS
CN Benzene, 1-fluoro-4-nitro- (CA INDEX NAME)



RN 394-41-2 HCAPLUS
CN Phenol, 3-fluoro-4-nitro- (CA INDEX NAME)



RN 430-51-3 HCAPLUS
CN 2-Propanone, 1-fluoro- (8CI, 9CI) (CA INDEX NAME)



RN 455-14-1 HCAPLUS
CN Benzenamine, 4-(trifluoromethyl)- (CA INDEX NAME)



RN 502-42-1 HCAPLUS
CN Cycloheptanone (CA INDEX NAME)

RN 504-29-0 HCAPLUS
CN 2-Pyridinamine (CA INDEX NAME)

RN 534-07-6 HCAPLUS
CN 2-Propanone, 1,3-dichloro- (CA INDEX NAME)



RN 540-37-4 HCAPLUS
CN Benzenamine, 4-iodo- (CA INDEX NAME)



RN 542-85-8 HCAPLUS
CN Ethane, isothiocyanato- (CA INDEX NAME)



RN 654-70-6 HCAPLUS
CN Benzonitrile, 4-amino-2-(trifluoromethyl)- (CA INDEX NAME)

RN 695-34-1 HCAPLUS
CN 2-Pyridinamine, 4-methyl- (CA INDEX NAME)

RN 1191-95-3 HCAPLUS
CN Cyclobutanone (CA INDEX NAME)

RN 1194-02-1 HCAPLUS
CN Benzonitrile, 4-fluoro- (CA INDEX NAME)

RN 1197-55-3 HCAPLUS
CN Benzeneacetic acid, 4-amino- (CA INDEX NAME)



RN 1427-07-2 HCAPLUS
CN Benzene, 2-fluoro-1-methyl-4-nitro- (CA INDEX NAME)



RN 1445-73-4 HCAPLUS
CN 4-Piperidinone, 1-methyl- (CA INDEX NAME)

RN 2393-17-1 HCAPLUS
CN Benzenepropanoic acid, 4-amino- (CA INDEX NAME)



RN 15118-60-2 HCAPLUS
CN Benzenebutanoic acid, 4-amino- (CA INDEX NAME)



RN 24424-99-5 HCAPLUS
CN Dicarbonic acid, C,C'-bis(1,1-dimethylethyl) ester (CA INDEX NAME)



RN 31230-17-8 HCAPLUS
CN 1H-Pyrazol-3-amine, 5-methyl- (CA INDEX NAME)



RN 34667-88-4 HCAPLUS
CN Benzonitrile, 2-fluoro-4-nitro- (CA INDEX NAME)



RN 54356-04-6 HCAPLUS
CN Propanoic acid, 3-(triphenylphosphoranylidene)-, ethyl ester (CA INDEX NAME)



RN 57260-71-6 HCAPLUS
CN 1-Piperazinecarboxylic acid, 1,1-dimethylethyl ester (CA INDEX NAME)

RN 177662-76-9 HCAPLUS
CN Benzenamine, 4-(methylsulfonyl)-, hydrochloride (1:1) (CA INDEX NAME)



IT 399-95-1P, 4-Amino-3-fluorophenol 403-24-7P, 2-Fluoro-4-nitrobenzoic acid 619-45-4P, 4-Aminobenzoic acid methyl ester 2182-38-9P, 2-Methyl-2-phenylaminopropanenitrile 6636-88-0P, 1-[(4-Methylphenyl)amino]cyclopentanecarbonitrile 26850-26-0P, 2-(4-Hydroxyphenylamino)-2-methylpropanenitrile 49830-37-7P, 1-Aminocyclopentanecarbonitrile 53312-80-4P , 4-Amino-2-fluorobenzonitrile 55793-49-2P, 1-Methylaminocyclopentanecarbonitrile 70441-12-2P, 1-[(4-Methylphenyl)amino]cyclohexanecarbonitrile 71026-66-9P, (4-Aminophenyl)carbamic acid tert-butyl ester 92647-69-3P, 1-[(4-Methylphenyl)amino]cycloheptanecarbonitrile 101568-43-8P, 2-Methyl-2-[(4-methylphenyl)amino]propanenitrile 107553-81-1P, 4-[(Cyanodimethylmethyl)amino]benzoic acid methyl ester 143782-23-4P, 4-Isothiocyanato-2-trifluoromethylbenzonitrile 154263-08-8P, 1-Methylaminocyclobutanecarbonitrile 170911-92-9P, 4-(4-Aminophenyl)piperazine-1-carboxylic acid tert-butyl ester 915086-27-0P, [4-[(1-Cyano-1-methylethyl)amino]phenyl]carbamic acid tert-butyl ester 915086-28-1P, [4-[3-(4-Cyano-3-trifluoromethylphenyl)-4-imino-5,5-dimethyl-2-thioxoimidazolidin-1-yl]phenyl]carbamic acid tert-butyl ester 915086-31-6P, 4-[3-(4-Hydroxyphenyl)-5-imino-4,4-dimethyl-2-thioxoimidazolidin-1-yl]-2-trifluoromethylbenzonitrile 915086-34-9P, 4-[3-(4-Methylphenyl)-5-imino-4,4-dimethyl-2-thioxoimidazolidin-1-yl]-2-trifluoromethylbenzonitrile 915086-37-2P, 1-[(4-Methylphenyl)amino]cyclobutanecarbonitrile 915086-41-8P, 4-[4-Imino-2-thioxo-1-(4-methylphenyl)-1,3-diazaspiro[4.5]decan-3-yl]-2-trifluoromethylbenzonitrile 915086-42-9P, 4-[4-Imino-2-thioxo-1-(4-methylphenyl)-1,3-diazaspiro[4.6]undecan-3-yl]-2-trifluoromethylbenzonitrile 915086-45-2P, 1-[(4-Hydroxyphenyl)amino]cyclobutanecarbonitrile 915086-46-3P, 2-Methyl-2-[(2-carboxyphenyl)amino]propanenitrile 915086-48-5P, 1-[(Biphenyl-4-yl)amino]cyclobutanecarbonitrile

915086-50-9P, 1-[(2-Naphthyl)amino]cyclobutanecarbonitrile
915086-52-1P, 2-[(4-Methyl-2-pyridinyl)amino]-2-methylpropanenitrile 915086-54-3P, 2-[(2-Pyridinyl)amino]-2-methylpropanenitrile 915086-56-5P, 1-[(5-Methyl-1H-pyrazol-3-yl)amino]cyclobutanecarbonitrile 915086-60-1P, 3-Fluoro-2-methyl-2-[(4-methylphenyl)amino]propionitrile 915086-62-3P, 2-Methyl-2-[(4-trifluoromethylphenyl)amino]propanenitrile 915086-64-5P, 3-Chloro-2-chloromethyl-2-[(4-methylphenyl)amino]propanenitrile 915086-67-8P, 1-[(2-Methylphenyl)amino]cyclobutanecarbonitrile 915086-69-0P, 4-(4-Imino-2-thioxo-1,3-diazaspiro[4.4]nonan-3-yl)-2-trifluoromethylbenzonitrile 915086-73-6P, 1-Methyl-4-(4-methylphenylamino)piperidine-4-carbonitrile 915086-74-7P, 4-[4-Imino-8-methyl-2-thioxo-1-(4-methylphenyl)-1,3,8-triazaspiro[4.5]decan-3-yl]-2-trifluoromethylbenzonitrile 915086-80-5P, 1-[(4-Hydroxymethylphenyl)amino]cyclobutanecarbonitrile 915086-86-1P, 3-[4-(1-Cyanocyclobutylamino)phenyl]propionic acid 915086-92-9P, 4-[4-(1-Cyanocyclobutylamino)phenyl]butyric acid 915086-99-6P, 4-[4-(1-Cyanocyclobutylamino)phenyl]piperazine-1-carboxylic acid tert-butyl ester 915087-04-6P, (E)-3-[4-[7-(4-Cyano-3-trifluoromethylphenyl)-8-oxo-6-thioxo-5,7-diazaspiro[3.4]octan-5-yl]phenyl]acrylic acid 915087-06-8P, 1-[(4-Methylsulfonylphenyl)amino]cyclobutanecarbonitrile 915087-08-0P, [4-(1-Cyanocyclobutylamino)phenyl]acetic acid 915087-20-6P, 4-(1-Cyanocyclobutylamino)benzoic acid 915087-24-0P, N-Methyl-2-fluoro-4-nitrobenzamide 915087-25-1P, N-Methyl-2-fluoro-4-aminobenzamide 915087-26-2P, N-Methyl-4-(1-cyanocyclobutylamino)-2-fluorobenzamide 915087-28-4P, 1-(2-Fluoro-4-hydroxyphenylamino)cyclobutanecarbonitrile 915087-30-8P, 4-(1-Cyanocyclopentylamino)-2-fluorobenzonitrile 915087-32-0P, N-Methyl-2-fluoro-4-[(1,1-dimethylcyanomethyl)amino]benzamide 915087-34-2P, N-Methyl-2-fluoro-4-[(1-cyanocyclopentyl)amino]benzamide 915087-36-4P, 4-[4-(2,2,2-Trifluoroacetylamino)phenyl]butanoic acid 915087-37-5P, N,N-Dimethyl-4-[4-(2,2,2-Trifluoroacetylamino)phenyl]butanamide 915087-38-6P, N,N-Dimethyl-4-(4-aminophenyl)butanamide 915087-39-7P, N,N-Dimethyl-4-[4-(1-cyanocyclobutylamino)phenyl]butanamide
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of diarylhydantoin compds. as androgen receptor antagonists useful against hormone refractory prostate cancer)

RN 399-95-1 HCAPLUS
CN Phenol, 4-amino-3-fluoro- (CA INDEX NAME)



RN 403-24-7 HCAPLUS
CN Benzoic acid, 2-fluoro-4-nitro- (CA INDEX NAME)



RN 619-45-4 HCAPLUS
CN Benzoic acid, 4-amino-, methyl ester (CA INDEX NAME)



RN 2182-38-9 HCAPLUS
CN Propanenitrile, 2-methyl-2-(phenylamino)- (CA INDEX NAME)

RN 6636-88-0 HCAPLUS
CN Cyclopentanecarbonitrile, 1-[(4-methylphenyl)amino]- (CA INDEX NAME)



RN 26850-26-0 HCAPLUS
CN Propanenitrile, 2-[(4-hydroxyphenyl)amino]-2-methyl- (CA INDEX NAME)



RN 49830-37-7 HCAPLUS
CN Cyclopentanecarbonitrile, 1-amino- (CA INDEX NAME)

RN 53312-80-4 HCAPLUS
CN Benzonitrile, 4-amino-2-fluoro- (CA INDEX NAME)



RN 55793-49-2 HCAPLUS
CN Cyclopentanecarbonitrile, 1-(methylamino)- (CA INDEX NAME)

RN 70441-12-2 HCAPLUS
CN Cyclohexanecarbonitrile, 1-[(4-methylphenyl)amino]- (CA INDEX NAME)



RN 71026-66-9 HCAPLUS
CN Carbamic acid, N-(4-aminophenyl)-, 1,1-dimethylethyl ester (CA INDEX NAME)



RN 92647-69-3 HCAPLUS
CN Cycloheptanecarbonitrile, 1-[(4-methylphenyl)amino]- (CA INDEX NAME)



RN 101568-43-8 HCAPLUS
CN Propanenitrile, 2-methyl-2-[(4-methylphenyl)amino]- (CA INDEX NAME)



RN 107553-81-1 HCAPLUS
CN Benzoic acid, 4-[(1-cyano-1-methylethyl)amino]-, methyl ester (CA INDEX NAME)



RN 143782-23-4 HCAPLUS
CN Benzonitrile, 4-isothiocyanato-2-(trifluoromethyl)- (CA INDEX NAME)

RN 154263-08-8 HCAPLUS
CN Cyclobutanecarbonitrile, 1-(methylamino)- (CA INDEX NAME)

RN 170911-92-9 HCAPLUS
CN 1-Piperazinecarboxylic acid, 4-(4-aminophenyl)-, 1,1-dimethylethyl ester (CA INDEX NAME)



RN 915086-27-0 HCAPLUS
CN Carbamic acid, [4-[(1-cyano-1-methylethyl)amino]phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 915086-28-1 HCAPLUS
CN Carbamic acid, [4-[3-[4-cyano-3-(trifluoromethyl)phenyl]-4-imino-5,5-dimethyl-2-thioxo-1-imidazolidinyl]phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 915086-31-6 HCAPLUS
CN Benzonitrile, 4-[3-(4-hydroxyphenyl)-5-imino-4,4-dimethyl-2-thioxo-1-imidazolidinyl]-2-(trifluoromethyl)- (CA INDEX NAME)



RN 915086-34-9 HCAPLUS
CN Benzonitrile, 4-[5-imino-4,4-dimethyl-3-(4-methylphenyl)-2-thioxo-1-imidazolidinyl]-2-(trifluoromethyl)- (CA INDEX NAME)



RN 915086-37-2 HCAPLUS
CN Cyclobutanecarbonitrile, 1-[(4-methylphenyl)amino]- (CA INDEX NAME)



RN 915086-41-8 HCAPLUS
CN Benzonitrile, 4-[4-imino-1-(4-methylphenyl)-2-thioxo-1,3-diazaspiro[4.5]dec-3-yl]-2-(trifluoromethyl)- (CA INDEX NAME)



RN 915086-43-0 HCAPLUS
CN Benzonitrile, 4-[4-imino-1-(4-methylphenyl)-2-thioxo-1,3-diazaspiro[4.6]undec-3-yl]-2-(trifluoromethyl)- (CA INDEX NAME)



RN 915086-45-2 HCAPLUS
CN Cyclobutanecarbonitrile, 1-[(4-hydroxyphenyl)amino]- (CA INDEX NAME)



RN 915086-46-3 HCAPLUS
CN Benzoic acid, 2-[(1-cyano-1-methylethyl)amino]- (CA INDEX NAME)



RN 915086-48-5 HCAPLUS
CN Cyclobutanecarbonitrile, 1-([1,1'-biphenyl]-4-ylamino)- (CA INDEX NAME)



RN 915086-50-9 HCAPLUS
CN Cyclobutanecarbonitrile, 1-(2-naphthalenylamino)- (CA INDEX NAME)



RN 915086-52-1 HCAPLUS
CN Propanenitrile, 2-methyl-2-[(4-methyl-2-pyridinyl)amino]- (CA INDEX NAME)



RN 915086-54-3 HCAPLUS
CN Propanenitrile, 2-methyl-2-(2-pyridinylamino)- (CA INDEX NAME)



RN 915086-56-5 HCAPLUS
CN Cyclobutanecarbonitrile, 1-[(5-methyl-1H-pyrazol-3-yl)amino]- (CA INDEX NAME)



RN 915086-60-1 HCAPLUS
CN Propanenitrile, 3-fluoro-2-methyl-2-[(4-methylphenyl)amino]- (CA INDEX NAME)



RN 915086-62-3 HCAPLUS
CN Propanenitrile, 2-methyl-2-[[4-(trifluoromethyl)phenyl]amino]- (CA INDEX NAME)



RN 915086-64-5 HCAPLUS
CN Propanenitrile, 3-chloro-2-(chloromethyl)-2-[(4-methylphenyl)amino]- (CA INDEX NAME)



RN 915086-67-8 HCAPLUS
CN Cyclobutanecarbonitrile, 1-[(2-methylphenyl)amino]- (CA INDEX NAME)



RN 915086-69-0 HCAPLUS
CN Benzonitrile, 4-(4-imino-2-thioxo-1,3-diazaspiro[4.4]non-3-yl)-2-(trifluoromethyl)- (CA INDEX NAME)



RN 915086-73-6 HCAPLUS
CN 4-Piperidinecarbonitrile, 1-methyl-4-[(4-methylphenyl)amino]- (CA INDEX NAME)



RN 915086-74-7 HCAPLUS
CN Benzonitrile, 4-[4-imino-8-methyl-1-(4-methylphenyl)-2-thioxo-1,3,8-triazaspiro[4.5]dec-3-yl]-2-(trifluoromethyl)- (CA INDEX NAME)



RN 915086-80-5 HCAPLUS
CN Cyclobutanecarbonitrile, 1-[[4-(hydroxymethyl)phenyl]amino]- (CA INDEX NAME)



RN 915086-86-1 HCAPLUS
CN Benzenepropanoic acid, 4-[(1-cyanocyclobutyl)amino]- (CA INDEX NAME)



RN 915086-92-9 HCAPLUS
CN Benzenebutanoic acid, 4-[(1-cyanocyclobutyl)amino]- (CA INDEX NAME)



RN 915086-99-6 HCAPLUS

CN 1-Piperazinecarboxylic acid, 4-[4-[(1-cyanocyclobutyl)amino]phenyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)



RN 915087-04-6 HCAPLUS
CN 2-Propenoic acid, 3-[4-[7-[4-cyano-3-(trifluoromethyl)phenyl]-8-oxo-6-thioxo-5,7-diazaspiro[3.4]oct-5-yl]phenyl]-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.



RN 915087-06-8 HCAPLUS
CN Cyclobutanecarbonitrile, 1-[[4-(methylsulfonyl)phenyl]amino]- (CA INDEX NAME)



RN 915087-08-0 HCAPLUS
CN Benzeneacetic acid, 4-[(1-cyanocyclobutyl)amino]- (CA INDEX NAME)



RN 915087-20-6 HCAPLUS
CN Benzoic acid, 4-[(1-cyanocyclobutyl)amino]- (CA INDEX NAME)



RN 915087-24-0 HCAPLUS
CN Benzamide, 2-fluoro-N-methyl-4-nitro- (CA INDEX NAME)



RN 915087-25-1 HCAPLUS
CN Benzamide, 4-amino-2-fluoro-N-methyl- (CA INDEX NAME)



RN 915087-26-2 HCAPLUS
CN Benzamide, 4-[(1-cyanocyclobutyl)amino]-2-fluoro-N-methyl- (CA INDEX NAME)



RN 915087-28-4 HCAPLUS
CN Cyclobutanecarbonitrile, 1-[(2-fluoro-4-hydroxyphenyl)amino]- (CA INDEX NAME)



RN 915087-30-8 HCAPLUS
CN Benzonitrile, 4-[(1-cyanocyclopentyl)amino]-2-fluoro- (CA INDEX NAME)



RN 915087-32-0 HCAPLUS
CN Benzamide, 4-[(1-cyano-1-methylethyl)amino]-2-fluoro-N-methyl- (CA INDEX NAME)



RN 915087-34-2 HCAPLUS
CN Benzamide, 4-[(1-cyanocyclopentyl)amino]-2-fluoro-N-methyl- (CA INDEX NAME)



RN 915087-36-4 HCAPLUS
CN Benzenebutanoic acid, 4-[(2,2,2-trifluoroacetyl)amino]- (CA INDEX NAME)



RN 915087-37-5 HCAPLUS
CN Benzenebutanamide, N,N-dimethyl-4-[(2,2,2-trifluoroacetyl)amino]- (CA INDEX NAME)



RN 915087-38-6 HCAPLUS
CN Benzenebutanamide, 4-amino-N,N-dimethyl- (CA INDEX NAME)



RN 915087-39-7 HCAPLUS
CN Benzenebutanamide, 4-[(1-cyanocyclobutyl)amino]-N,N-dimethyl- (CA INDEX NAME)



IT 5470-49-5P, 4-Methylsulfonylphenylamine
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of diarylhydantoin compds. as androgen receptor antagonists useful against hormone refractory prostate cancer)
RN 5470-49-5 HCAPLUS
CN Benzenamine, 4-(methylsulfonyl)- (CA INDEX NAME)



REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 2 OF 2 HCAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2005:1154369 HCAPLUS Full-text
DOCUMENT NUMBER: 143:432632
TITLE: Androgen receptor-based methods and materials for assessing prostate cancer therapies, and compounds
INVENTOR(S): Jung, Michael E.; Ouk, Samedy; Sawyers, Charles L.; Chen, Charlie D.; Welsbie, Derek

PATENT ASSIGNEE(S): The Regents of the University of California, USA
SOURCE: PCT Int. Appl., 44 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005099693	A2	20051027	WO 2005-US5529	20050223
WO 2005099693	A3	20060126		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2005232526	A1	20051027	AU 2005-232526	20050223
US 20070191443	A1	20070816	US 2006-590445	20060824
US 20080090888	A2	20080417		

PRIORITY APPLN. INFO.: US 2004-547101P P 20040224
WO 2005-US5529 W 20050223

OTHER SOURCE(S): MARPAT 143:432632
GI



I

AB A modest (2-5 fold) increase in androgen receptor (AR) mRNA is the only expression change consistently associated with developing resistance to antiandrogen therapy. Increased levels of AR confer resistance to antiandrogens by amplifying signal output from low levels of residual ligand and altering the normal response to antagonists. The invention provides cell-based assays for use in the examination of new therapeutic modalities and provides for the design of antiandrogen compds. The invention further provides azido compds. which bind to the ligand-binding domain of the androgen receptor and inhibit prostate cancer growth. Preparation of such compds., e.g. I, is described.

IT 362607-76-9, Kallikrein 2
RL: BSU (Biological study, unclassified); BIOL (Biological study) (methods and materials for assessing prostate cancer therapies and compds.)

RN 362607-76-9 HCAPLUS
CN Kallikrein 2 (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
IT 290585-91-0 323463-63-4, GenBank AL582808
RL: BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study)
(methods and materials for assessing prostate cancer therapies and compds.)
RN 290585-91-0 HCAPLUS
CN DNA (human cell line MGC3 clone IMAGE:3944195 EST (expressed sequence tag)) (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
RN 323463-63-4 HCAPLUS
CN DNA (human cell line RAMOS CELL LINE clone CS0DL008YF05 EST (expressed sequence tag)) (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
IT 90357-06-5, Bicalutamide
RL: PAC (Pharmacological activity); BIOL (Biological study)
(methods and materials for assessing prostate cancer therapies and compds.)
RN 90357-06-5 HCAPLUS
CN Propanamide, N-[4-cyano-3-(trifluoromethyl)phenyl]-3-[(4-fluorophenyl)sulfonyl]-2-hydroxy-2-methyl- (CA INDEX NAME)



IT 75-86-5 654-70-6 148860-64-1 88192-19-2
88192-20-5 148759-41-5 349553-73-7
867338-62-3 867338-63-4
RL: RCT (Reactant); RACT (Reactant or reagent)
(methods and materials for assessing prostate cancer therapies and compds.)
RN 75-86-5 HCAPLUS
CN Propanenitrile, 2-hydroxy-2-methyl- (CA INDEX NAME)

RN 654-70-6 HCAPLUS
CN Benzonitrile, 4-amino-2-(trifluoromethyl)- (CA INDEX NAME)

RN 14860-64-1 HCAPLUS
CN Benzenamine, 4-azido- (CA INDEX NAME)



RN 88192-19-2 HCAPLUS
CN 1-Propanamine, 3-azido- (CA INDEX NAME)

RN 88192-20-5 HCAPLUS
CN 1-Butanamine, 4-azido- (CA INDEX NAME)

RN 148759-41-5 HCAPLUS
CN 1-Pentanamine, 5-azido- (CA INDEX NAME)

RN 349553-73-7 HCAPLUS
CN 1-Hexanamine, 6-azido- (CA INDEX NAME)

RN 867338-62-3 HCAPLUS
CN 1-Heptanamine, 7-azido- (CA INDEX NAME)

RN 867338-63-4 HCAPLUS

CN 1-Octanamine, 8-azido- (CA INDEX NAME)

RESULTS FROM REGISTRY, CAPLUS, AND USPATFULL

=> d que stat l22
L13 STR



VAR G1=23/25
NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS 27

STEREO ATTRIBUTES: NONE
L15 18 SEA FILE=REGISTRY SSS FUL L13
L16 5 SEA FILE=HCAPLUS ABB=ON L15
L17 3 SEA FILE=HCAPLUS ABB=ON L16 AND ?PROSTATE?(5A)(?CANCER? OR CELL?)
L19 5 SEA FILE=HCAPLUS ABB=ON L16 OR L17
L20 3 SEA FILE=HCAPLUS ABB=ON L19 AND (PRD<20040224 OR PD<20040224)

L21 3 SEA FILE=USPATFULL ABB=ON L19 AND (PRD<20040224 OR PD<20040224)
L22 6 DUP REMOV L20 L21 (0 DUPLICATES REMOVED)

=> d ibib abs hitstr l22 1-6

L22 ANSWER 1 OF 6 USPATFULL on STN
ACCESSION NUMBER: 2001:18495 USPATFULL Full-text
TITLE: Androgen receptor suppressors in the therapy and diagnosis of prostate cancer, alopecia and other hyper-androgenic syndromes
INVENTOR(S): Sovak, Milos, La Jolla, CA, United States
Seligson, Allen L., San Marcos, CA, United States
Douglass, III, James Gordon, San Diego, CA, United States
Campion, Brian, Leucadia, CA, United States
Brown, Jason W., San Diego, CA, United States
PATENT ASSIGNEE(S): Biophysica, Inc., La Jolla, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 6184249	B1	20010206	<--
APPLICATION INFO.:	US 1998-215351		19981218 (9)	

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted

PRIMARY EXAMINER: Higel, Floyd D.
ASSISTANT EXAMINER: Sackey, Ebenezer
LEGAL REPRESENTATIVE: Rowland, Bertram I.Rae-Venter Law Group, P.C.
NUMBER OF CLAIMS: 7
EXEMPLARY CLAIM: 1
LINE COUNT: 985
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Substituted phenylalanines are provided comprising an hydantoin, urea or 2-hydroxyl, 2-methylpropionyl group, dimers thereof and alkyl, polyfluoroamido and haloarylamino derivatives thereof, as well as radiolabeled derivatives thereof. The compounds bind specifically to the androgen receptor and find use in the therapy of indications associated with the androgen receptor, such as, hirsutism, acne and androgenetic alopecia, and in the therapy and diagnosis of cell hyperplasia dependent on androgens.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT 279228-95-4P
(preparation of amides and ureas as androgen receptor suppressors)
RN 279228-95-4 USPATFULL
CN Butanamide, N-[4-[3-[4-cyano-3-(trifluoromethyl)phenyl]-5,5-dimethyl-4-oxo-2-thioxo-1-imidazolidinyl]butyl]-2,2,3,3,4,4,4-heptafluoro- (CA INDEX NAME)



L22 ANSWER 2 OF 6 HCAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2000:441763 HCAPLUS Full-text
DOCUMENT NUMBER: 133:73866
TITLE: Preparation of amides and ureas as androgen receptor suppressors
INVENTOR(S): Sovak, Milos; Seligson, Allen L.; Douglas, James Gordon, III; Campion, Brian; Brown, Jason W.
PATENT ASSIGNEE(S): Biophysica, Inc., USA
SOURCE: PCT Int. Appl., 33 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 4
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000037430	A2	20000629	WO 1999-US26862	19991112 <--
WO 2000037430	A3	20030417		
W: AU, CZ, HU, IL, JP, NO, PL, SK, ZA				

RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE

US 6184249	B1	20010206	US 1998-215351	19981218	<--
EP 1144366	A2	20011017	EP 1999-958948	19991112	<--
EP 1144366	A3	20030604			
EP 1144366	B1	20070627			

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI, CY

AT 365707	T	20070715	AT 1999-958948	19991112	<--
PRIORITY APPLN. INFO.:			US 1998-215351	A 19981218	<--
			WO 1999-US26862	W 19991112	<--

OTHER SOURCE(S): MARPAT 133:73866

GI



I



II

AB The title compds. [I; X = NO2, CN, halo; V = CF3, halo, H; W = OH when T = H, and W = Me when T and T1 are taken together to form a C:Z bridge; U = N when T and T1 are taken together to form a C:Z bridge or is taken together with T1 to form a bond or O, S or N; n = 1-2 and d = 0-1; Y = a bond, C1-10 linking group containing heteroatoms; Z, when other than taken together with Y, = (un)saturated aliphatic , polyfluoroacrylamidoalkyl] and their radiolabeled derivs. which bind specifically to the androgen receptor and find use in indication associated with the androgen receptor, such as cell hyperplasia dependent on androgens, hirsutism, acne and androgenetic alopecia, were prepared Thus, treatment of 4-nitro-3-trifluoromethyl-N-(2,3- epoxy-2-methylpropionyl)aniline in MeOH with NH3 in preassure reactor followed by reacting 4-nitro-3-trifluoromethyl-N-(2-hydroxy-2-methyl-3-aminopropionyl)aniline with haptafluorobutyryl chloride afforded II. Biol. data for compds. I were given.

IT 279228-95-4P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of amides and ureas as androgen receptor suppressors)

RN 279228-95-4 HCAPLUS

CN Butanamide, N-[4-[3-[4-cyano-3-(trifluoromethyl)phenyl]-5,5-dimethyl-4-oxo-2-thioxo-1-imidazolidinyl]butyl]-2,2,3,3,4,4,4-heptafluoro- (CA INDEX NAME)



L22 ANSWER 3 OF 6 USPATFULL on STN
ACCESSION NUMBER: 1998:104761 USPATFULL Full-text
TITLE: Taxoids
INVENTOR(S): Bressi, Jerome C., San Diego, CA, United States
Douglass, III, James G., San Diego, CA, United States
Seligson, Allen, Poway, CA, United States
Sovak, Milos, LaJolla, CA, United States
PATENT ASSIGNEE(S): Biophysica Foundation, LaJolla, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 5801191		19980901	<--
APPLICATION INFO.:	US 1995-457674		19950601	(8)

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Trinh, Ba K.
LEGAL REPRESENTATIVE: Trecartin, Richard F.
NUMBER OF CLAIMS: 23
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 10 Drawing Figure(s); 10 Drawing Page(s)
LINE COUNT: 941
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Novel taxoids are provided having enhanced water solubility and/or improved pharmacological properties as compared to paclitaxel. The subject taxoids comprise a functional group attached to a paclitaxel at the C-2' and/or C-7 position by a linking group. Functional groups present in the subject taxoids may be hydrophilic chains, groups capable of in vivo conversion to hydrophilic chains, targeting moieties capable of specifically binding with cellular receptors and water soluble polymers of at least 5 kD. The subject taxoids find use in the treatment of hosts suffering from a cellular proliferative disease.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT 186040-53-9P, BP 196
(novel taxoids as antiproliferative agents)
RN 186040-53-9 USPATFULL
CN Benzenepropanoic acid, β-(benzoylamino)-α-hydroxy-, (2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-6,12b-bis(acetyloxy)-12-(benzoyloxy)-4-[[[[2-[3-[4-cyano-3-(trifluoromethyl)phenyl]-5,5-dimethyl-4-oxo-2-thioxo-1-imidazolidinyl]ethyl]amino]carbonyl]oxy]-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-11-hydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl ester, (αR,βS)- (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B

PAGE 2-A

IT 185946-99-0
(novel taxoids as antiproliferative agents)
RN 185946-99-0 USPATFULL
CN Benzonitrile, 4-[3-(2-aminoethyl)-4,4-dimethyl-5-oxo-2-thioxo-1-imidazolidinyl]-2-(trifluoromethyl)- (CA INDEX NAME)



L22 ANSWER 4 OF 6 HCAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1997:148858 HCAPLUS Full-text
DOCUMENT NUMBER: 126:162276
ORIGINAL REFERENCE NO.: 126:31288h,31289a
TITLE: Androgenic receptor-binding phenylthiohydantoins for diagnosis and treatment of prostate cancer
INVENTOR(S): Sovak, Milos; Bressi, Jerome C.; Douglass, James Gordon, III; Campion, Brian; Wrasidlo, Wolfgang
PATENT ASSIGNEE(S): Biophysica Foundation, USA; Sovak, Milos; Bressi, Jerome C.; Douglass, James Gordon, III; Campion, Brian; Wrasidlo, Wolfgang
SOURCE: PCT Int. Appl., 32 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9700071	A1	19970103	WO 1996-US10286	19960613 <--
W: AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG				
RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA				
US 5656651	A	19970812	US 1995-491130	19950616 <--
CA 2225484	A1	19970103	CA 1996-2225484	19960613 <--
AU 9663329	A	19970115	AU 1996-63329	19960613 <--
AU 712609	B2	19991111		
EP 854716	A1	19980729	EP 1996-922463	19960613 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
JP 10510845	T	19981020	JP 1996-503330	19960613 <--

PRIORITY APPLN. INFO.: US 1995-491130 A 19950616 <--
WO 1996-US10286 W 19960613 <--

OTHER SOURCE(S): MARPAT 126:162276
GI



I

AB Substituted phenylthiohydantoins (I; X, Y = O, S, NH; R = aliphatic, aryl, or aralkyl linking group) are provided for use in detecting tumor cells having androgenic receptors. These compds. can be used for specific targeting to the androgenic receptor-containing cells of cytostatic and/or cytotoxic agents, heavy or light radioactive or radiopaque atoms, etc. for detection and treatment of cancer cells containing androgenic receptors (e.g. prostate cancer cells). Thus, cycloaddn. of 2-[[[N-(tert-butoxycarbonyl)amino]ethyl]amino]-2- cyanopropane to 2-trifluoromethyl-4-isothiocyanatobenzonitrile produced I (X = NH, Y = S, R = CH2CH2NHCO2Bu-t) (BP-136), which was converted to the unprotected aminoethyl derivative (BP-138) with HCl. BP-138 was conjugated with 2'-(triethylsilyloxy)-7-(p-nitrophenoxycarbonyl)paclitaxel (preparation given) to produce a targeted cytotoxic agent.

IT 185946-99-0P 186798-84-5P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(androgenic receptor-binding phenylthiohydantoins for diagnosis and treatment of prostate cancer)

RN 185946-99-0 HCAPLUS
CN Benzonitrile, 4-[3-(2-aminoethyl)-4,4-dimethyl-5-oxo-2-thioxo-1-imidazolidinyl]-2-(trifluoromethyl)- (CA INDEX NAME)



RN 186798-84-5 HCAPLUS
CN Benzenepropanamide, N-[2-[3-[4-cyano-3-(trifluoromethyl)phenyl]-5,5-dimethyl-4-oxo-2-thioxo-1-imidazolidinyl]ethyl]-4-hydroxy- (CA INDEX NAME)

PAGE 1-A



PAGE 2-A

IT 186040-53-9P 186798-65-2P 186798-70-9P
186798-71-0P 186798-85-6P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(androgenic receptor-binding phenylthiohydantoins for diagnosis and treatment of prostate cancer)

RN 186040-53-9 HCAPLUS

CN Benzenepropanoic acid, β-(benzoylamino)-α-hydroxy-, (2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-6,12b-bis(acetyloxy)-12-(benzoyloxy)-4-[[[[2-[3-[4-cyano-3-(trifluoromethyl)phenyl]-5,5-dimethyl-4-oxo-2-thioxo-1-imidazolidinyl]ethyl]amino]carbonyl]oxy]-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-11-hydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl ester, (αR,βS)- (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B

PAGE 2-A

RN 186798-65-2 HCAPLUS
CN Carbamic acid, [2-[3-[4-cyano-3-(trifluoromethyl)phenyl]-5,5-dimethyl-4-oxo-2-thioxo-1-imidazolidinyl]ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 186798-70-9 HCAPLUS
CN Acetamide, N-[2-[3-[4-cyano-3-(trifluoromethyl)phenyl]-5,5-dimethyl-4-oxo-2-thioxo-1-imidazolidinyl]ethyl]- (CA INDEX NAME)



RN 186798-71-0 HCAPLUS
CN Glycinamide, N-[[(triphenylmethyl)thio]acetyl]glycyl-N-[2-[3-[4-cyano-3-(trifluoromethyl)phenyl]-5,5-dimethyl-4-oxo-2-thioxo-1-imidazolidinyl]ethyl]- (9CI) (CA INDEX NAME)



RN 186798-85-6 HCAPLUS
CN Benzenepropanamide, N-[2-[3-[4-cyano-3-(trifluoromethyl)phenyl]-5,5-dimethyl-4-oxo-2-thioxo-1-imidazolidinyl]ethyl]-4-hydroxy-3,5-diiodo- (CA INDEX NAME)

PAGE 1-A



PAGE 2-A

IT 186798-95-8P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(androgenic receptor-binding phenylthiohydantoins for diagnosis and treatment of prostate cancer)

RN 186798-95-8 HCAPLUS

CN Benzenepropanoic acid, β-(benzoylamino)-α-[(triethylsilyl)oxy]-, (2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-6,12b-bis(acetyloxy)-12-(benzoyloxy)-4-[[[[2-[3-[4-cyano-3-(trifluoromethyl)phenyl]-5,5-dimethyl-4-oxo-2-thioxo-1-imidazolidinyl]ethyl]amino]carbonyl]oxy]-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-11-hydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl ester, (αR,βS)- (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B

PAGE 2-A

L22 ANSWER 5 OF 6 USPATFULL on STN

ACCESSION NUMBER:	97:71085 USPATFULL Full-text	
TITLE:	Androgenic directed compositions	
INVENTOR(S):	Sovak, Milos, La Jolla, CA, United States	
	Bressi, Jerome C., San Diego, CA, United States	
	Douglass, III, James Gordon, San Diego, CA, United States	
	Campion, Brian, Solana Beach, CA, United States	
	Wrasidlo, Wolfgang, La Jolla, CA, United States	
PATENT ASSIGNEE(S):	Biophysica Inc., La Jolla, CA, United States (U.S. corporation)	

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 5656651		19970812	<--
APPLICATION INFO.:	US 1995-491130		19950616	(8)

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Higel, Floyd D.
LEGAL REPRESENTATIVE: Flehr Hohbach Test Albritton & Herbert LLP
NUMBER OF CLAIMS: 7
EXEMPLARY CLAIM: 1
LINE COUNT: 767
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Substituted phenylthiohydantoins are provided for use in detecting the presence of tumor cells having androgenic receptors and providing for cytostatic and cytotoxic activity toward such cells. The subject compounds provide for vehicles for specific targeting to the androgenic receptor containing cells of cytostatic and/or cytotoxic agents, heavy or light radioactive or radioopaque atoms, and the like for detection and treatment of cancer cells involving androgenic receptors or blocking androgenic receptors.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT 185946-99-0P 186798-84-5P
(androgenic receptor-binding phenylthiohydantoins for diagnosis and treatment of prostate cancer)
RN 185946-99-0 USPATFULL
CN Benzonitrile, 4-[3-(2-aminoethyl)-4,4-dimethyl-5-oxo-2-thioxo-1-imidazolidinyl]-2-(trifluoromethyl)- (CA INDEX NAME)



RN 186798-84-5 USPATFULL
CN Benzenepropanamide, N-[2-[3-[4-cyano-3-(trifluoromethyl)phenyl]-5,5-dimethyl-4-oxo-2-thioxo-1-imidazolidinyl]ethyl]-4-hydroxy- (CA INDEX NAME)

PAGE 1-A



PAGE 2-A

IT 186040-53-9P 186798-65-2P 186798-70-9P
186798-71-0P 186798-85-6P
(androgenic receptor-binding phenylthiohydantoins for diagnosis and treatment of prostate cancer)

RN 186040-53-9 USPATFULL

CN Benzenepropanoic acid, β-(benzoylamino)-α-hydroxy-, (2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-6,12b-bis(acetyloxy)-12-(benzoyloxy)-4-[[[[2-[3-[4-cyano-3-(trifluoromethyl)phenyl]-5,5-dimethyl-4-oxo-2-thioxo-1-imidazolidinyl]ethyl]amino]carbonyl]oxy]-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-11-hydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl ester, (αR,βS)- (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B

PAGE 2-A

RN 186798-65-2 USPATFULL
CN Carbamic acid, [2-[3-[4-cyano-3-(trifluoromethyl)phenyl]-5,5-dimethyl-4-oxo-2-thioxo-1-imidazolidinyl]ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 186798-70-9 USPATFULL
CN Acetamide, N-[2-[3-[4-cyano-3-(trifluoromethyl)phenyl]-5,5-dimethyl-4-oxo-2-thioxo-1-imidazolidinyl]ethyl]- (CA INDEX NAME)



RN 186798-71-0 USPATFULL
CN Glycinamide, N-[[(triphenylmethyl)thio]acetyl]glycyl-N-[2-[3-[4-cyano-3-(trifluoromethyl)phenyl]-5,5-dimethyl-4-oxo-2-thioxo-1-imidazolidinyl]ethyl]- (9CI) (CA INDEX NAME)



RN 186798-85-6 USPATFULL
CN Benzenepropanamide, N-[2-[3-[4-cyano-3-(trifluoromethyl)phenyl]-5,5-dimethyl-4-oxo-2-thioxo-1-imidazolidinyl]ethyl]-4-hydroxy-3,5-diiodo- (CA INDEX NAME)

PAGE 1-A



PAGE 2-A

IT 186798-95-8P
(androgenic receptor-binding phenylthiohydantoins for diagnosis and treatment of prostate cancer)

RN 186798-95-8 USPATFULL

CN Benzenepropanoic acid, β-(benzoylamino)-α-[(triethylsilyl)oxy]-, (2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-6,12b-bis(acetyloxy)-12-(benzoyloxy)-4-[[[[2-[3-[4-cyano-3-(trifluoromethyl)phenyl]-5,5-dimethyl-4-oxo-2-thioxo-1-imidazolidinyl]ethyl]amino]carbonyl]oxy]-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-11-hydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl ester, (αR,βS)- (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B

PAGE 2-A

L22 ANSWER 6 OF 6 HCAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1997:105187 HCAPLUS Full-text
DOCUMENT NUMBER: 126:113164
ORIGINAL REFERENCE NO.: 126:21733a,21736a
TITLE: Novel taxoids as antiproliferative agents
INVENTOR(S): Sovak, Milos; Douglass, James G.; Bressi, Jerome C.; Seligson, Allen
PATENT ASSIGNEE(S): Biophysica Foundation, USA; Sovak, Milos; Douglass, James G.; Bressi, Jerome C.; Seligson, Allen
SOURCE: PCT Int. Appl., 55 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9638138	A1	19961205	WO 1996-US8245	19960531 <--
W: AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI				
RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN				
US 5801191	A	19980901	US 1995-457674	19950601 <--
CA 2222299	A1	19961205	CA 1996-2222299	19960531 <--
CA 2222299	C	20010410		
AU 9659622	A	19961218	AU 1996-59622	19960531 <--
AU 713097	B2	19991125		
EP 833628	A1	19980408	EP 1996-916900	19960531 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
JP 10509461	T	19980914	JP 1996-536740	19960531 <--
JP 3425955	B2	20030714		
PRIORITY APPLN. INFO.:			US 1995-457674 A	19950601 <--
			WO 1996-US8245 W	19960531 <--

OTHER SOURCE(S): MARPAT 126:113164

AB Novel taxoids are provided having enhanced water solubility and/or improved pharmacol. properties as compared to paclitaxel. The subject taxoids comprise a functional group attached to a paclitaxel at the C-2' and/or C-7 position by a linking group. Functional groups present in the subject taxoids may be hydrophilic chains, groups capable of in vivo conversion to hydrophilic chains, targeting moieties capable of specifically binding with cellular receptors and water soluble polymers of at least 5 kD. The subject taxoids find use in the treatment of hosts suffering from a cellular proliferative disease.

IT 186040-53-9P, BP 196
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(novel taxoids as antiproliferative agents)

RN 186040-53-9 HCAPLUS

CN Benzenepropanoic acid, β-(benzoylamino)-α-hydroxy-, (2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-6,12b-bis(acetyloxy)-12-(benzoyloxy)-4-[[[[2-[3-[4-cyano-3-(trifluoromethyl)phenyl]-5,5-dimethyl-4-oxo-2-thioxo-1-imidazolidinyl]ethyl]amino]carbonyl]oxy]-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-11-hydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl ester, (αR,βS)- (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B

PAGE 2-A

IT 185946-99-0
RL: RCT (Reactant); RACT (Reactant or reagent)
(novel taxoids as antiproliferative agents)
RN 185946-99-0 HCAPLUS
CN Benzonitrile, 4-[3-(2-aminoethyl)-4,4-dimethyl-5-oxo-2-thioxo-1-imidazolidinyl]-2-(trifluoromethyl)- (CA INDEX NAME)


CH2— CH2— NH2
Me
N
S
Me
N
O
F3C
CN

SEARCH HISTORY

=> d his ful

(FILE 'HOME' ENTERED AT 10:03:09 ON 15 JUL 2008)

FILE 'HCAPLUS' ENTERED AT 10:04:08 ON 15 JUL 2008
E JUNG MICHAEL E/AU
L1 295 SEA ABB=ON "JUNG MICHAEL E"/AU
E OUK SAMEDY/AU
L2 11 SEA ABB=ON "OUK SAMEDY"/AU
E SAWYERS CHARLES L/AU
L3 148 SEA ABB=ON ("SAWYERS CHARLES"/AU OR "SAWYERS CHARLES L"/AU OR "SAWYERS CHARLES W"/AU)
E CHEN CHARLIE D/AU
L4 11 SEA ABB=ON ("CHEN CHARLIE D"/AU OR "CHEN CHARLIE DEGUI"/AU)
E WELSBIE DEREK/AU
L5 9 SEA ABB=ON ("WELSBIE DEREK"/AU OR "WELSBIE DEREK S"/AU OR "WELSBIE DEREK STUART"/AU)
L6 2 SEA ABB=ON L1 AND L2 AND L3 AND L4 AND L5
SELECT RN L6 1-2

FILE 'REGISTRY' ENTERED AT 10:05:21 ON 15 JUL 2008
L7 212 SEA ABB=ON (654-70-6/BI OR 75-86-5/BI OR 90357-06-5/BI OR 101568-43-8/BI OR 103-72-0/BI OR 106-49-0/BI OR 106-50-3/BI OR 107553-81-1/BI OR 108-94-1/BI OR 118-92-3/BI OR 1191-95-3/BI OR 1194-02-1/BI OR 1197-55-3/BI OR 120-92-3/BI OR 123-30-8/BI OR 1427-07-2/BI OR 143782-23-4/BI OR 1445-73-4/BI OR 14860-64-1/BI OR 148759-41-5/BI OR 150-13-0/BI OR 15118-60-2/BI OR 154262-93-8/BI OR 154262-97-2/BI OR 154262-99-4/BI OR 154263-01-1/BI OR 154263-08-8/BI OR 155180-53-3/BI OR 170911-92-9/BI OR 177338-09-9/BI OR 177662-76-9/BI OR 2182-38-9/BI OR 2393-17-1/BI OR 24424-99-5/BI OR 26850-26-0/BI OR 290585-91-0/BI OR 31230-17-8/BI OR 323463-63-4/BI OR 34667-88-4/BI OR 349553-73-7/BI OR 350-46-9/BI OR 362607-76-9/BI OR 394-41-2/BI OR 399-95-1/BI OR 403-24-7/BI OR 430-51-3/BI OR 455-14-1/BI OR 49830-37-7/BI OR 502-42-1/BI OR 504-29-0/BI OR 53312-80-4/BI OR 534-07-6/BI OR 540-37-4/BI OR 542-85-8/BI OR 54356-04-6/BI OR 5470-49-5/BI OR 55793-49-2/BI OR 57260-71-6/BI OR 619-45-4/BI OR 62-53-3/BI OR 6636-88-0/BI OR 67-64-1/BI OR 695-34-1/BI OR 70441-12-2/BI OR 71026-66-9/BI OR 867338-62-3/BI OR 867338-63-4/BI OR 88192-19-2/BI OR 88192-20-5/BI OR 91-59-8/BI OR 915086-27-0/BI OR 915086-28-1/BI OR 915086-29-2/BI OR 915086-30-5/BI OR 915086-31-6/BI OR 915086-32-7/BI OR 915086-33-8/BI OR 915086-34-9/BI OR 915086-35-0/BI OR 915086-36-1/BI OR 915086-37-2/BI OR 915086-38-3/BI OR 915086-39-4/BI OR 915086-40-7/BI OR 915086-41-8/BI OR 915086-42-9/BI OR 915086-43-0/BI OR 915086-44-1/BI OR 915086-45-2/BI OR 915086-46-3/BI OR 915086-47-4/BI OR 915086-48-5/BI OR 915086-49-6/BI OR 915086-50-9/BI OR 915086-51-0/BI OR 915086-52-1/BI OR 915086-53-2/BI OR 915086-54-3/BI OR 915086-55-4/BI OR 915086-56-5/BI OR 915086-57-6/BI OR 915086-58-7/BI OR 915086-59-8/BI OR 915086-60-1/BI OR 915086-61-2/BI OR 915086-62-3/BI OR 915086-63-4/BI OR 915086-64-5/BI OR 915086-65-6/BI OR 915086-66-7/BI OR 915086-67-8/BI OR 915086-68-9/BI OR 915086-69-0/BI OR 915086-70-3/BI OR 915086-71-4/BI OR 915086-72-5/BI OR 915086-73-6/BI OR 915086-74-7/BI OR 915086-75-8/BI

FILE 'HCAPLUS' ENTERED AT 10:05:42 ON 15 JUL 2008

```
L8            2 SEA ABB=ON  L6 AND L7

     FILE 'REGISTRY' ENTERED AT 10:07:08 ON 15 JUL 2008
L9              STR
L10           0 SEA SSS SAM L9
L11             STR L9
L12          21 SEA SSS SAM L11
L13             STR L11
L14           1 SEA SSS SAM L13
L15          18 SEA SSS FUL L13

     FILE 'HCAPLUS' ENTERED AT 10:24:29 ON 15 JUL 2008
L16           5 SEA ABB=ON  L15
L17           3 SEA ABB=ON  L16 AND ?PROSTATE?(5A)(?CANCER? OR CELL?)
L18           5 SEA ABB=ON  L16 AND (?EXOGEN? OR ?WILD? OR ?ANDROGEN? OR
                ?RECEPT? OR ?POLYNUCLEOTID? OR ?HORMON? OR ?REFRACT?)
L19           5 SEA ABB=ON  L16 OR L17
L20           3 SEA ABB=ON  L19 AND (PRD<20040224 OR PD<20040224)

     FILE 'USPATFULL' ENTERED AT 10:29:28 ON 15 JUL 2008
L21           3 SEA ABB=ON  L19 AND (PRD<20040224 OR PD<20040224)

     FILE 'HCAPLUS, USPATFULL' ENTERED AT 10:29:41 ON 15 JUL 2008
L22           6 DUP REMOV L20 L21 (0 DUPLICATES REMOVED)

     FILE HOME

     FILE HCAPLUS

     Copyright of the articles to which records in this database refer is
     held by the publishers listed in the PUBLISHER (PB) field (available
     for records published or updated in Chemical Abstracts after December
     26, 1996), unless otherwise indicated in the original publications.
     The CA Lexicon is the copyrighted intellectual property of the
     the American Chemical Society and is provided to assist you in searching
     databases on STN.  Any dissemination, distribution, copying, or storing
     of this information, without the prior written consent of CAS, is
     strictly prohibited.

     FILE COVERS 1907 - 15 Jul 2008  VOL 149 ISS 3
     FILE LAST UPDATED: 14 Jul 2008  (20080714/ED)

     HCAplus now includes complete International Patent Classification (IPC)
     reclassification data for the second quarter of 2008.

     New CAS Information Use Policies, enter HELP USAGETERMS for details.

      This file contains CAS Registry Numbers for easy and accurate
      substance identification.

     FILE REGISTRY
     Property values tagged with IC are from the ZIC/VINITI data file
     provided by InfoChem.

     STRUCTURE FILE UPDATES:   14 JUL 2008  HIGHEST RN 1034013-75-6
     DICTIONARY FILE UPDATES:  14 JUL 2008  HIGHEST RN 1034013-75-6

     New CAS Information Use Policies, enter HELP USAGETERMS for details.

     TSCA INFORMATION NOW CURRENT THROUGH January 9, 2008.
```

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

FILE USPATFULL
FILE COVERS 1971 TO PATENT PUBLICATION DATE: 15 Jul 2008 (20080715/PD)
FILE LAST UPDATED: 15 Jul 2008 (20080715/ED)
HIGHEST GRANTED PATENT NUMBER: US7401362
HIGHEST APPLICATION PUBLICATION NUMBER: US20080168588
CA INDEXING IS CURRENT THROUGH 15 Jul 2008 (20080715/UPCA)
ISSUE CLASS FIELDS (/INCL) CURRENT THROUGH: 15 Jul 2008 (20080715/PD)
REVISED CLASS FIELDS (/NCL) LAST RELOADED: Jun 2008
USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE: Jun 2008

USPATFULL now includes complete International Patent Classification (IPC) reclassification data for the second quarter of 2008.